

CURRICULUM VITAE: SIR RORY EDWARDS COLLINS

- Born:** 3 January 1955, Hong Kong
- H-index:** 167 (Scopus)
- Degrees:** FRCP (Honorary), London (2016)
Fellow, Royal Society (2015)
Fellow, Academy of Medical Sciences, London (2004)
FRCP (Honorary), Edinburgh (2002)
MA, Oxford University (1986)
MSc (Applied Statistics), Oxford University (1983)
MB BS, St Thomas's Hospital Medical School, University of London (1981)
LMSSA, London (1980)
BSc (Applied Statistics), George Washington University (1977)
- Present post:** Head, Nuffield Department of Population Health, University of Oxford (2013-)
Principal Investigator & Chief Executive, UK Biobank (2005-)
British Heart Foundation Professor of Medicine & Epidemiology, Oxford (1996-)
Honorary Consultant, Oxfordshire Primary Care Trust and then Oxford University Hospitals Trust (1991-)
Co-director with Professor Sir Richard Peto, Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), University of Oxford (1986-)
- Previous posts:** British Heart Foundation Senior Research Fellow (1986-96)
Research Assistant (Honorary Senior House Officer, Registrar & Senior Registrar), Department of Cardiovascular Medicine, John Radcliffe Hospital, and Clinical Trial Service Unit, Radcliffe Infirmary, Oxford (1981-91)
House Physician, North Staffordshire Royal Infirmary (1981)
House Surgeon, St Thomas's Hospital (1980-81)
Research Assistant, Biostatistics Centre, George Washington University, Washington DC, USA (1976-77)
- Honorary posts:** Honorary Professor of Medicine and Epidemiology, Division of Cardiovascular Sciences, University of Manchester (2021-)
Adjunctive Professor, Reiwa Tokai University, Japan (2013-)
Honorary Director, China Oxford Centre for International Health Research (2005-)
Honorary Professor, Beijing Union Medical College and Chinese Academy of Medical Sciences (2004-)
- Awards:** AHA Ron Haddock International Impact Award (2022)
EAS Anitschkow Prize in Atherosclerosis Research (2021)
MRC Millennium Medal (2020)
International Okamoto Award (2020)
Keynote Speaker, European Society of Hypertension (ESH) and International Society of Hypertension (ISH) Congress (2020)
Sir Arthur Thomson Trust Lecture: UK Biobank, University of Birmingham (2020)
Scientific Session Lecture, Vall d'Hebron Institute of Research, Barcelona (2019)
Paul Hamilton Wood Lecture, Cardiology Update London (2019)
George Pickering Lecture, British and Irish Hypertension Society (2018)
Honorary Fellowship, British Pharmacological Society (2017)
McMaster University, Honorary Doctorate (2017)
Paul Dudley White International Lecture, American Heart Association (2017)
International Okamoto Award, Japan Vascular Disease Research Foundation (2016)
JJ Sampson Lecture, University of California San Francisco (2016)
Warwick University, Honorary Degree of Doctor of Science (2015)
Very Reverend Derek Hole lecture, University of Leicester (2014)
Ambuj Nath Bose Medal, Royal College of Physicians (2014)
Mackenzie Medal, British Cardiovascular Society (2014)
Gold Medal, European Society of Cardiology, (2014)
Robert L Krakoff International Lecture, Harvard Medical School (2013)

Discovery Lecture, Vanderbilt University Medical Center (2013)
 Geoffrey Rose Lecture, European Society of Cardiology (2012)
 Joy Edelman Lecture, British Cardiovascular Society (2012)
 William Harvey Lecture, Royal Society of Medicine/Harveian Society (2012)
 Inaugural Faculty Lecture, Faculty of Pharmaceutical Medicine (2011)
 Knighthood for services to Science (2011)
 Honorary Fellowship, Royal College of Physicians Faculty of Public Health (2009)
 J Allyn Taylor International Prize in Medicine (2007)
 Sir Anthony Dawson Lecture, Queen Mary's School of Medicine (2006)
 Queen's Anniversary Prize for Higher and Further Education to the University of Oxford for CTSU's research studies (2006-10)
 Honorary Fellowship, Royal College of Physicians, Faculty of Pharmaceutical Medicine (2004)
 Pfizer Medal for Innovative Science (2004)
 Fernandez-Cruz Foundation Memorial Lecture (2003)
 Lars Werkö Lecture, Swedish Heart Association (2003)
 Bronte-Stewart Lecture, University of Glasgow (2003)
 Visiting Professor, Institute for International Health, University of Sydney (2003)
 Archie Cochrane Lecture, Green College (2002)
 Lord Rayner Memorial Lecture, Royal College of Physicians (2001)
 Senior Aspirin Award (2000; jointly with C Baigent, R Peto, P Sleight)
 Fothergill Medal, Medical Society of London (1998; jointly with R Peto)
 Prix Raymond Bourguin for Achievement in Cancer Research (1996; jointly with R Peto, R Gray, M Clarke & J Godwin)
 Travelling Fellowship for genetic epidemiology, British Heart Foundation (1995)
 European Award for Excellence in Stroke Research (1995; jointly with ZM Chen, JX Xie, R Peto & LS Liu)
 Visiting Professorship, Royal Society of Medicine Foundation (1994)
 Honorary Medal of the Polish Cardiac Society (1994)
 Evian Health Award to the ISIS-2 trial (1988)
 Staines Medical Research Fellowship, Exeter College, Oxford (1986-89)

Societies: Fellow, European Society of Cardiology (1994-)
 Fellow, British and Irish Hypertension Society (1993-)

Committees: *Research Steering Committees:*
Chair: Cholesterol Treatment Trialists' (CTT) Collaboration; HPS-3/TIMI 55 REVEAL trial of anacetrapib; ORION-4 trial of inclisiran; Treatment of HDL to Reduce the Incidence of Vascular Events (HPS-2/THRIVE) of niacin; UK Biobank
Member: BHF Centre for Research Excellence; China Kadoorie Biobank; Mexico City Prospective Study; Prospective Studies Collaboration (PSC)

Other Advisory Committees:
 University of Oxford Council
 McGill University, External Scientific Advisory Board
 Population Health Research Institute (McMaster University and Hamilton Health Sciences), International Advisory Board (Chair)
 Department of Health and Social Care (DHSC) Research Recovery, Resilience Oversight Group
 Oxford Playhouse Board (representing St John's College)

Top 20 Publications

Cholesterol Treatment Trialists' (CTT) Collaborators (writing committee: Baigent C, Reith C, Emberson J, **Collins R**, Preiss D, Spata E, Halls H, Holland L, Armitage A, Blackwell L. Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy. *Lancet* 2022; 400: 832-45 [34 citations]

Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, Lange F, Andersson JLR, Griffanti L, Duff E, Jbabdi S, Taschler B, Keating P, Winkler AM, **Collins R**, Matthews PM, Allen N, Miller KL, Nichols TE, Smith SM. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *Nature* 2022; 604: 697-707 [562 citations]

Akbari P, Gilani A, Sosina O, Kosmicki JA, Khrimian L, Fang YY, Persaud T, Garcia V, Sun D, Li A, Mbatchou J, Locke AE, Benner C, Verweij N, Lin N, Hossain S, Agostinucci K, Pascale JV, Dirice E, Dunn M; Regeneron Genetics Center; DiscovEHR Collaboration, Kraus WE, Shah SH, Chen YI, Rotter JI, Rader DJ, Melander O, Still CD, Mirshahi T, Carey DJ, Berumen-Campos J, Kuri-Morales P, Alegre-Díaz J, Torres JM, Emberson JR, **Collins R**, Balasubramanian S, Hawes A, Jones M, Zambrowicz B, Murphy AJ, Paulding C, Coppola G, Overton JD, Reid JG, Shuldiner AR, Cantor M, Kang HM, Abecasis GR, Karalis K, Economides AN, Marchini J, Yancopoulos GD, Sleeman MW, Altarejos J, Della Gatta G, Tapia-Conyer R, Schwartzman ML, Baras A, Ferreira MAR, Lotta LA. Sequencing of 640,000 exomes identifies *GPR75* variants associated with protection from obesity. *Science* 2021; 373: 8683 [91 citations]

Collins R, Bowman L, Landray M, Peto R. The Magic of Randomization versus the Myth of Real-World Evidence. *New Eng J Med* 2020; 382: 674-678 [297 citations]

Mafham M, Spata E, Goldacre R, Gair D, Curnow P, Bray M, Hollings S, Roebuck C, Gale C, Mamas M, Deanfield J, de Belder M, Luescher T, Denwood T, Landray M, Emberson J, **Collins R**, Morris E, Casadei B, Baigent B. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. *Lancet* 2020; 396: 381-389 [618 citations]

Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, Bennett DA, Chen Y, Dong C, Hu R, Zhou G, Yu B, Jia W, Parish S, Clarke R, Davey Smith G, **Collins R**, Holmes MV, Li L, Peto R, Chen Z; China Kadoorie Biobank Collaborative Group. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. *Lancet* 2019; 393: 1831-1842 [322 citations]

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016; 388: 2532-2561 [1704 citations]

Alegre-Díaz J, Herrington W, López-Cervantes M, Gnatiuc L, Ramirez R, Hill M, Baigent C, McCarthy M, Lewington S, **Collins R**, Whitlock G, Tapia-Conyer R, Peto R, Kuri-Morales P, Emberson J. Diabetes and cause-specific mortality in Mexico City. *N Engl J Med* 2016; 375:1961-71 [270 citations]

Reith C, Landray M, Devereaux PJ, Bosch J, Granger CB, Baigent C, Califf RM, **Collins R**, Yusuf S. Randomized clinical trials — removing unnecessary obstacles. *New Engl J Med* 2013; 369: 1061-65 [117 citations]

Cholesterol Treatment Trialists' (CTT) Collaboration. (writing committee: Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, **Collins R**, Baigent C) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012; 380: 581-90 [910 citations]

Cholesterol Treatment Trialists' (CTT) Collaboration (writing committee: Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, Peto R, Barnes EH, Keech A, Simes J, **Collins R**). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010; 376: 1670-81 [3123 citations]

Cholesterol Treatment Trialists' (CTT) Collaborators (writing committee: Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Simes J, **Collins R**). Efficacy and safety of cholesterol-lowering treatment: meta-analysis of individual data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005; 366: 1267-78 [6804 citations]

Heart Protection Study Collaborative Group (writing committee: **Collins R**, Armitage J, Parish S, Sleight P, Peto R). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360: 7-22 [9135 citations]

Prospective Studies Collaboration (writing committee: Lewington S, Clarke R, Qizilbash N, Peto R, **Collins R**). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of one million adults in 61 prospective studies. *Lancet* 2002; 360: 1903-13 [14095 citations]

Antithrombotic Trialists' (ATT) Collaboration (writing committee: Baigent C, Sudlow C, **Collins R**, Peto R). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. *BMJ* 2002; 324: 71-86 [8902 citations]

Antiplatelet Trialists' Collaboration (writing committee: **Collins R**, Peto R, Baigent C, Sandercock P, Dunbabin D, Warlow C). Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994; 308: 81-106 [4939 citations]

Fibrinolytic Therapy Trialists' Collaborative Group (authors: **Collins R**, Baigent C, Sleight P, Peto R). Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. *Lancet* 1994; 343: 311-22 [2821 citations]

MacMahon S, Peto R, Cutler J, **Collins R**, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990; 335: 765-74 [5942 citations]

Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part II. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. *Lancet* 1990; 335: 827-38 [5273 citations]

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (authors: **Collins R**, Parish S, Sleight P, Peto R). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 1988; ii: 349-60 [5444 citations]

Yusuf, S, **Collins R**, Peto R. Why do we need some large, simple, randomized trials? *Stats in Med* 1984; 3: 409-20 [931 citations]

PUBLICATIONS

1981

Forbat L, **Collins R**, Maskell G, Sonksen P. Glucose concentrations in parotid fluid and venous blood of patients attending a diabetic clinic. *J Roy Soc Med* 1981; 74: 725-28

Collins R. Presentation and analysis of the results of clinical trials in cardio-vascular disease. *Brit Med J* 1981; 283: 232-33 (letter)

1983

Collins R, Yusuf S. Glucose-insulin-potassium infusion in acute myocardial infarction. *Am J Cardiol* 1983; 51: 566 (letter)

1984

Yusuf S, **Collins R**, Peto R. Why do we need some large, simple, randomized trials? *Statistics in Medicine* 1984; 3: 409-20

1985

Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. *Brit Med J* 1985; 290: 17-23

Peto R, Yusuf S, **Collins R**. Cholesterol-lowering trial results in their epidemiologic context. *Circulation* 1985; 72: III-451 (abstract)

Yusuf S, Peto R, Lewis J, **Collins R**, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. *Prog Cardiovasc Dis* 1985; 27: 335-71

Collins R, Langman M. Treatment with histamine H₂ antagonists in acute upper gastrointestinal haemorrhage. *New Engl J Med* 1985; 313: 660-66

Yusuf S, **Collins R**, Peto R, Furburg C, Stampfer M, Goldhaber SZ, Hennekens CH. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side effects from 33 randomized controlled trials. *Eur Heart J* 1985; 6: 556-85

Collins R, Chalmers I, Peto R. Antihypertensive treatment in pregnancy. *BMJ* 1985; 291: 1129 (letter)

1986

ISIS-1 (First International Study of Infarct Survival) Collaborative Group. A randomized trial of intravenous atenolol among 16,027 patients with suspected acute myocardial infarction: ISIS-1. *Lancet* 1986; ii: 57-66

Collins R, Langman M. Histamine H₂ antagonists in acute upper gastro-intestinal haemorrhage. *New Engl J Med* 1986; 314: 717 (letter)

1987

Yusuf S, **Collins R**, Lim L, Sterry H, Pearson M, Sleight P. Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction. *Am J Cardiol* 1987; 59: 245-50

Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. *Statistics in Medicine* 1987; 6: 245-50

ISIS (International Study of Infarct Survival) Pilot Study Investigators. Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. *Eur Heart J* 1987; 8: 634-42

Collins R, Peto R, Sleight P for the ISIS Steering Committee. Intravenous streptokinase given within 0-4 hours of onset of myocardial infarction reduced mortality in ISIS-2. *Lancet* 1987; i: 502 (letter)

1988

Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolus and in venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic and urologic surgery. *New Engl J Med* 1988; 318: 1162-73

Peto R, Gray R, **Collins R**, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R. Randomised trial of prophylactic daily aspirin among male British doctors. *Brit Med J* 1988; 296: 313-16

Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet therapy. *Brit Med J* 1988; 296: 320-31

ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. *Lancet* 1988; i: 921-23

Yusuf S, **Collins R**, MacMahon S, Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. *Lancet* 1988; i: 1088-92

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *Lancet* 1988; ii: 349-60

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. *J Am Coll Cardiol* 1988; 12: 3A-13A

Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. *N Engl J Med* 1988; 319: 1681-91

MacMahon S, **Collins R**, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. *JAMA* 1988; 260: 1910-16

Collins R, Peto R, Sleight P. Significant reduction in mortality with streptokinase given 7-24 hours after pain onset. *Lancet* 1988; ii: 1187-88 (letter)

1989

Hirsh J, Salzman E, Harker L, Fuster V, Dalen J, Cairns J, **Collins R**. Aspirin and other platelet active drugs: relationship among dose, effectiveness and side effects. *Chest* 1989; 95: 12S-18S

Cairns J, **Collins R**, Fuster V, Passamani E. Coronary thrombolysis. *Chest* 1989; 95: 73S-87S

Hennekens CH, Buring JE, Sandercock P, **Collins R**, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. *Circulation* 1989; 80: 749-56

Chen ZM, **Collins R**, Peto R, Li WX. Serum cholesterol levels and stroke mortality. *N Engl J Med* 1989; 321: 1339-40 (letter)

Collins R, Wallenberg HCS. Pharmacological prevention and treatment of hypertensive disorders in pregnancy. Pp.512-533 in: Effective Care in Pregnancy and Childbirth (ed Chalmers I, Enkin M, Keirse MJNC). Oxford University Press 1989

Peto R, **Collins R**, Sleight P. Wider inclusion criteria needed for thrombolytic therapy. *Ann Int Med* 1989; 111: 540 (letter)

1990

Hennekens CH, Buring JE, Sandercock PAG, Gray R, Wheatley K, **Collins R**, Doll R, Peto R. Aspirin use and chronic diseases. *BMJ* 1990; 300: 117-18 (letter)

MacMahon S, Peto R, Cutler J, **Collins R**, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part I. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990; 335: 765-74

Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part II. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. *Lancet* 1990; 335: 827-38

Peto R, **Collins R**. Benefits of thrombolysis. *BMJ* 1990; 300: 1196 (letter)

Collins R, Peto R, Godwin J, MacMahon S. Blood pressure and coronary heart disease. *Lancet* 1990; 336: 370-71 (letter)

Buring JE, Hennekens CH, Sandercock P, **Collins R**, Peto R. Aspirin and stroke. *Arch Neurol* 1990; 47: 1353-54

Byar DP, Schoenfeld DA, Green SB, Amato D, Davis R, De Gruttola V, Finkelstein DM, Gatsonis C, Gelber RD, Lagakos S, Lefkopoulou M, Tsiatis A, Zelen M, Peto J, Freedman LS, Gail M, Simon R, Ellenberg SS, Anderson JR, **Collins R**, Peto R, Peto T. Design considerations for AIDS trials. *N Engl J Med* 1990; 323: 1343-48

Early Breast Cancer Trialists' Collaborative Group. Treatment of Early Breast Cancer. Volume 1: Worldwide Evidence 1985-1990. Oxford University Press 1990

Collins R, Flather M, Peto R. GISSI-2: 10% reduction in mortality with heparin in acute myocardial infarction? *Lancet* 1990; 336: 439-40 (letter)

Collins R. Thrombolysis: an overview of the effects of different thrombolytic agents on mortality and on morbidity. Pp.66-69 in: The Management of Acute Myocardial Ischaemia (ed Chamberlain DA, Julian DG, Sleight P). Chapman & Hall, London, 1990

1991

Alexopoulos D, **Collins R**, Adamopoulos S, Peto R, Sleight P. Holter monitoring of ventricular arrhythmias in a randomised controlled study of intravenous streptokinase in acute myocardial infarction. *Brit Heart J* 1991; 65: 9-13

European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. *Lancet* 1991; 337: 1235-43

Collins R. Antiplatelet agents for IUGR and pre-eclampsia. In: Chalmers I (ed): Oxford Database of Perinatal Trials, Version 1.2, Disk Issue 5, February 1991, Record 4000

Boon N, **Collins R**. Streptokinase. In: Therapeutic Drugs, Volume 2 (ed. Dollery C). Churchill Livingstone 1991

Boon N, **Collins R**. Urokinase. In: Therapeutic Drugs, Volume 2 (ed. Dollery C). Churchill Livingstone 1991

Collins R, Julian D. British Heart Foundation Surveys (1987 and 1989) of United Kingdom policies for acute myocardial infarction. *Brit Heart J* 1991; 66: 250-55

Chen Z, Peto R, **Collins R**, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. *BMJ* 1991; 303: 276-82

Collins R. Orthopaedic surgeons and thromboprophylaxis. *BMJ* 1991; 303: 923 (letter)

Sun Z, Zhu Y, Stjernsward J, Hillman M, **Collins R**, Zhen Y, Hsia CC, Lu J, Huang F, Ni Z, Ni T, Liu GT, Yu Z, Liu Y, Chen JM, Peto R. Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study. *Cancer Detection & Prevention* 1991; 15: 313-18

Teo KK, Yusuf S, **Collins R**, Held PH, Peto R. Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. *BMJ* 1991; 303: 1499-1503

ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Fourth International Study of Infarct Survival: protocol for a large simple study of the effects of oral mononitrate, of oral captopril, and of intravenous magnesium. *Am J Cardiol* 1991; 68: 87D-100D

Collins R, Peto R. La necessità della metanalisi dei trial randomizzati: come evitare i bias e gli errori casuali nella valutazione degli effetti moderati di un trattamento. Pp.139-150 in: *Metodologia nella Ricerca Clinica* (ed: Angeleri F, Agnelli G, Provinciali L). Monduzzi Editore, Bologna, 1991

Atallah AN, **Collins R**, Peto R. Large and simple randomized clinical trial with low dose aspirin for prevention of low birth weight and perinatal mortality in Brazil. Pp.273-277 in: *Hypertension in Pregnancy* (ed Cosmi CV, Di-Renzo GC), World Congress of International Society of Hypertension in Pregnancy, Perugia, Italy. Monduzzi Editore, Bologna, 1991

1992

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. *Eur Heart J* 1992; 13: 594-98

Collins R, Doll R, Peto R. Ethics of clinical trials. In: *Introducing New Treatment for Cancer: Practical, Ethical and Legal Problems*. (Ed. Williams CJ) John Wiley & Sons Ltd, Chichester, 1992, pp.49-65

Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. *Lancet* 1992; 339: 1-15

Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. *Lancet* 1992; 339: 71-85

ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. *Lancet* 1992; 339: 753-70

Collins R, Peto R, Parish S, Sleight P. After ISIS-3. *Lancet* 1992; 339: 1226-7 (letter)

Smith RP, Meier P, Abrams D, **Collins R**, Peto R. Time for some really large, simple, randomized trials in HIV disease. *Oncology* 1992; 6: 6-7

Collins R, Keech A, Peto R, Sleight P, Kjekshus J, Wilhelmsen L, MacMahon S, Shaw J, Simes J, Braunwald E, Buring J, Hennekens C, Pfeffer M, Sacks F, Probstfield J, Yusuf S, Downs JR, Gotto A,

Cobbe S, Ford I, Shepherd J. Cholesterol and total mortality: need for larger trials. *BMJ* 1992; 304: 1689 (letter)

Department of Health Director of Research's Advisory Group on Health Technology Assessment. Assessing the effects of health technologies: principles, practice, proposals. (**Collins R**: member of Advisory Group.) Department of Health, London, 1992

Chalmers I, **Collins R**, Dickersin K. Controlled trials and meta-analyses can help resolve disagreements among orthopaedic surgeons. *J Bone Joint Surg* 1992; 74-B: 641-43 (editorial)

ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. In: Sleight P, Tavazzi L (eds). *The Major Clinical Trials on Thrombolysis for Acute Myocardial Infarction*. Raven Press Ltd, New York 1992

Collins R, Sleight P, Maggioni A. The risk of stroke after thrombolytic therapy. *N Engl J Med* 1992; 327: 1531 (letter)

1993

Pipilis A, Flather M, **Collins R**, Hargreaves A, Kolettis T, Boon N, Foster C, Appleby P, Sleight P. Effects on ventricular arrhythmias of oral captopril and of oral mononitrate started early in acute myocardial infarction: results of a randomised placebo controlled trial. *Brit Heart J* 1993; 69: 161-65

Collins R. Cholesterol lowering trials in their epidemiological context. *Postgrad Med J* 1993; 69 (Suppl): S3-S7

Chen Z, Keech A, **Collins R**, Slavin B, Chen J, Campbell TC, Peto R. Prolonged infection with hepatitis B virus and association between low blood cholesterol concentration and liver cancer. *BMJ* 1993; 306: 890-94

Peto R, **Collins R**. Immediate versus deferred zidovudine. *Lancet* 1993; 341: 1022-23 (letter)

Collins R, Peto R, Parish S, Sleight P. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. *Am J Cardiol* 1993; 71: 1127-28 (letter)

Pipilis A, Flather M, **Collins R**, Coats A, Conway M, Appleby P, Sleight P. Hemodynamic effects of captopril and isosorbide mononitrate started early in acute myocardial infarction: a randomized placebo controlled study. *J Am Coll Cardiol* 1993; 22: 73-79

Collins R. Systematic overview of randomized trials of cholesterol lowering. In: *Cholesterol Lowering Trials: Advice for the British Physician* (ed. Laker M, Neil A, Wood C). Royal College of Physicians of London on behalf of the British Hyperlipidaemia Association, 1993

EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. *Lancet* 1993; 342: 767-72

Gray R, Clarke M, **Collins R**, Peto R. The EBCTCG overview of adjuvant therapy of breast cancer. What are the implications for future studies? *Ann NY Acad Sci* 1993; 698: 339-48

1994

Antiplatelet Trialists' Collaboration (writing committee: **Collins R**, Peto R, Baigent C, Sandercock P, Dunbabin D, Warlow C). Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994; 308: 81-106

Antiplatelet Trialists' Collaboration (writing committee: **Collins R**, Peto R, Baigent C, Sandercock P, Dunbabin D, Warlow C). Collaborative overview of randomised trials of antiplatelet treatment. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. *BMJ* 1994; 308: 159-68

Antiplatelet Trialists' Collaboration (writing committee: **Collins R**, Peto R, Baigent C, Sandercock P, Dunbabin D, Warlow C). Collaborative overview of randomised trials of antiplatelet treatment. III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *BMJ* 1994; 308: 235-46

Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. *Lancet* 1994; 343: 311-22

CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. *Lancet* 1994; 343: 619-29

Keech A, **Collins R**, MacMahon S, Armitage J, Lawson A, Wallendszus K, Fatemian M, Kearney E, Lyon V, Mindell J, Mount J, Parish S, Painter R, Slavin B, Sleight P, Youngman L, Peto R for the Oxford Cholesterol Study Group. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. *Eur Heart J* 1994; 15: 255-69

Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. *Br Med Bull* 1994; 50: 272-98

Collins R. Antiplatelet agents for IUGR and pre-eclampsia. In: *Pregnancy and Childbirth Module* (Eds Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP), *Cochrane Database of Systematic Reviews: Review No. 04000*, Spring 1994. Published through "Cochrane Updates on Disk", Oxford: Update Software, 1994, Disk Issue 3

ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study Investigators. Randomized controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects. *Eur Heart J* 1994; 15: 608-19

Collins R, Baigent C, Peto R, Farrell B. Antiplatelet prophylaxis. *BMJ* 1994; 308: 651 (letter)

Baigent C, **Collins R**, Peto R, Bell P, Sandercock P on behalf of the Antiplatelet Trialists' Collaboration. Trials of antiplatelet therapy (Authors' reply). *BMJ* 1994; 308: 1372

Collins R, Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. Chapter 69, pp.1156-1164, in: *Textbook of Hypertension* (ed JD Swales). Blackwell, Oxford, 1994

Peto R, **Collins R**, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. *Ann NY Acad Sci* 1994, pp.314-40

Collins R, Flather M. Fourth International Study of Infarct Survival (ISIS-4). *Brit J Cardiol* 1994; 1(Suppl 1): S9-S12

MacMahon S, Rodgers A, **Collins R**, Farrell B. Antiplatelet therapy to prevent thrombosis after hip fracture: rationale for a randomised trial. *J Bone & Joint Surg* 1994; 76-B: 521-24

Collins R, Baigent C, Sandercock P, Peto for the Antiplatelet Trialists' Collaboration. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. *BMJ* 1994; 309: 1215-17

Peto R, **Collins R**. Randomization. *Nature* 1994; 372: 588 (letter)

Budaj A, **Collins R**, Cedro K, Cybulski J, Ptaszynska A, Ceremuzynski L. Treatment and clinical course of myocardial infarction in Polish and world centers participating in ISIS-4. *Polish Heart Journal* 1994; 41: 482

1995

Peto R, **Collins R**, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. *J Clin Epidemiol* 1995; 48: 23-40

MacMahon S, Rodgers A, **Collins R**, Farrell B. Antiplatelet therapy to prevent thrombosis after hip fracture. *J Bone Joint Surg* 1995; 77-B: 163-64

ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. *Lancet* 1995; 345: 669-85

Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). *Lancet* 1995; 345: 686-87

Gray R, Clarke M, **Collins R**, Peto R. La revisión del Early Breast Cancer Trialists' Collaborative Group (EBCTCG) sobre terapia adyuvante en cáncer de mama: implicaciones frente a futuros estudios. Chapter 62 in: *Mastología Dinamica* (ed E A Gardiol, A T Gomez). Ediciones Diaz de Santos SA, Madrid, 1995

Gray R, Clarke M, **Collins R**, Peto R. Making randomised trials larger: a simple solution? (Editorial) *Eur J Surg Oncol* 1995; 21: 137-39

Cholesterol Treatment Trialists (CTT) Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. *Am J Cardiol* 1995; 75: 1130-34

Parish S, **Collins R**, Peto R, Youngman L, Barton J, Jayne K, Clarke R, Appleby P, Lyon V, Cederholm-Williams S, Marshall J, Sleight P for the International Studies of Infarct Survival (ISIS) Collaborators. Cigarette smoking, tar yields, and non-fatal myocardial infarction: 14,000 cases and 32,000 controls in the United Kingdom. *BMJ* 1995; 311: 471-77

Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. *N Engl J Med* 1995; 333: 1444-55

Harris ML, Bron AJ, Brown NAP, Keech AC, Wallendszus KR, Armitage JA, MacMahon S, Snibson G, **Collins R** for the Oxford Cholesterol Study Group. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. *Br J Ophthalmol* 1995; 79: 996-1002

CLASP Collaborative Group. Low-dose aspirin in pregnancy and early childhood development: follow-up of the collaborative low-dose aspirin study in pregnancy. *Br J Obstet Gynaecol* 1995; 102: 861-68

Collins R, Baigent C, Peto R. Effects of streptokinase in patients presenting within 6 hours of prolonged chest pain with ST segment depression. *Br Heart J* 1995; 74: 573-74 (letter)

Collins R, Peto R, Sleight P for the ISIS Collaborative Group. ISIS-4. *Lancet* 1995; 345: 1374-75 (letter)

Collins R, Peto R. Risks and benefits of calcium antagonists. *Lancet* 1995; 346: 961-62 (letter)

1996

Collins R, Baigent C, Peto R. Benefit of heparin plus aspirin vs aspirin alone in unstable angina (letter). *JAMA* 1996; 276: 1873

Collins R, Peto R, Gray R, Parish S. Large-scale randomized evidence: trials and overviews. In: *Oxford Textbook of Medicine* (eds Weatherall D, Ledingham JGG, Warrell DA). Oxford University Press 1996

ECPPA Collaborative Group. ECPPA: randomised trial of low-dose aspirin for the prevention of maternal and fetal complications in high-risk pregnant women. *Br J Obstet Gyn* 1996; 103: 39-47

International Stroke Trial Pilot Study Collaborative Group. Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study. *J Neurology, Neurosurgery and Psychiatry* 1996; 60: 371-76

Keech AC, Armitage JM, Wallendszus KR, Lawson A, Hauer AJ, Parish SE, **Collins R** for the Oxford Cholesterol Study Group. Absence of effect of prolonged simvastatin therapy on nocturnal sleep in a large randomised placebo-controlled study. *Br J Clin Pharm* 1996; 42: 483-90

Mahaffey KW, Granger CB, **Collins R**, O'Connor CM, Ohman EM, Bleich SD, Col JJ, Califf RM. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. *Am J Cardiol* 1996; 77: 551-56

Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, Appleby P, Godwin J, Yusuf S, Peto R. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. *BMJ* 1996; 313: 652-59

Wardle J, Armitage J, **Collins R**, Wallendszus K, Keech A, Lawson A for the Oxford Cholesterol Study Group. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. *BMJ* 1996; 313: 75-78

Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. *Lancet* 1996; 348: 1189-96

Danesh J, Forman D, **Collins R**, Peto R. *Helicobacter pylori* screening and gastric cancer. *Lancet* 1996; 348: 758-59 (letter)

Collins R, Peto R. Magnesium therapy in acute myocardial infarction. *Am J Cardiol* 1996; 77: 329 (letter)

Chen ZM, Xie JX, Peto R, **Collins R**, Liu LS. Chinese Acute Stroke Trial (CAST): rationale, design and progress. *Cerebrovasc Dis* 1996; 6: 23 (abstract)

Peto R, Gray R, **Collins R**. Radiotherapy and surgery in early breast cancer. *N Engl J Med* 1996; 334: 989 (letter)

1997

Mitropoulos KA, Armitage JM, **Collins R**, Reeves BEA, Meade TW, Wallendszus KR, Wilson SS, Lawson A, Peto R for the Oxford Cholesterol Study Group. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. *Eur Heart J* 1997; 18: 235-41

Clarke R, Frost C, **Collins R**, Appleby P, Peto R. Dietary lipids and blood cholesterol: quantitative meta-analysis of metabolic ward studies. *BMJ* 1997; 314: 112-17

Collins R, Peto R. Magnesium in acute myocardial infarction. *Lancet* 1997; 349: 282-83 (letter)

Peto R, **Collins R**, Sackett D, Darbyshire J, Babiker A, Buyse M, Stewart H, Baum M, Goldhirsch A, Bonadonna G, Valagussa P, Rutqvist L, Elbourne D, Altman D, Dalesio O, Parmar M, Hill C, Clarke M,

Gray R, Doll R. The trials of Dr Bernard Fisher: a European perspective on an American episode. *Controlled Clinical Trials* 1997; 18: 1-13

Collins R, Peto R, Gray R, Parish S. Large-scale randomised evidence: trials and overviews. In: Maynard A, Chalmers I (eds). *Non-Random Reflections on Health Services Research: On the 25th Anniversary of Archie Cochrane's Effectiveness and Efficiency*. BMJ Publishing Group, London, 1997

Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. *N Engl J Med* 1997; 336: 847-60

Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization (writing committee: MacMahon S, Chalmers J, **Collins R**). Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. *J Hypertension* 1997; 15: 105-15

Liver Infusion Meta-analysis Group (writing committee: Gray R, Clarke M, **Collins R**, Peto R, Piedbois P, Mondor H, Buyse M). Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. *J Natl Cancer Inst* 1997; 89: 497-505

Meade TW, Wald N, **Collins R**. CONSORT statement on the reporting standards of clinical trials. Recommendations are inappropriate for trial reports. *BMJ* 1997; 314: 1126-27 (letter)

International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. *Lancet* 1997; 349: 1569-81

CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. *Lancet* 1997; 349: 1641-49

Consensus Statement: Prevention of venous thromboembolism (**Collins R**: member of Editorial Committee). *International Angiology* 1997; 16: 3-38

Chen ZM, Sandercock P, Xie JX, Peto R, **Collins R**, Liu LS. Hospital management of acute ischaemic stroke in China. *J Stroke Cerebrovasc Dis* 1997; 6: 361-67

Danesh J, **Collins R**, Peto R. Chronic infections and coronary heart disease: is there a link? *Lancet* 1997; 350: 430-36

Chen ZM, **Collins R**, Peto R, Xie JX, Liu LS on behalf of the CAST Collaborative Group. Interpretation of IST and CAST stroke trials. *Lancet* 1997; 350: 444 (letter)

Reperfusion Therapy Consensus Group (writing committee: Boersma H, Califf R, **Collins R**, Deckers JW, Simoons ML). Selection of reperfusion therapy for individual patients with evolving myocardial infarction. *Eur Heart J* 1997; 18: 1371-81

White HD, Aylward PE, Frey MJ, Adgey AAJ, Nair R, Hillis WS, Shalev Y, Brown MD, French JK, **Collins R**, Maraganore J, Adelman A on behalf of the Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). *Circulation* 1997; 96: 2155-61

MacMahon S, **Collins R**, Chalmers J. Reliable and unbiased assessment of the effects of calcium antagonists: importance of minimizing both systematic and random errors. *J Hypertension* 1997; 15: 1201-04

Chen Z, Xu Z, **Collins R**, Li W, Peto R. Early health effects of the emerging tobacco epidemic in China. *JAMA* 1997; 278: 1500-4

Chen ZM, **Collins R**, Peto R, Xie JX, Liu LS. Interpretation of IST and CAST stroke trials (letter). *Lancet* 1997; 350: 444

Collins R, Baigent C, Peto R. Reduced intensity of anticoagulation may be indicated (Authors' reply). *BMJ* 1997; 314: 222-23 (letter)

1998

Rotchell YE, Cruickshank JK, Phillips GM, Griffiths J, Stewart A, Farrell B, Ayers S, Hennis A, Grant A, Duley L, **Collins R**. Barbados Low-dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. *Br J Obs Gynae* 1998; 105:286-92

Malacrida R, Genoni M, Maggioni AP, Spataro V, Parish S, Palmer A, **Collins R**, Moccetti T for the Third International Study of Infarct Survival Collaborative Group. A comparison of the early outcome of acute myocardial infarction in women and men. *N Engl J Med* 1998; 338: 8-14

Baigent C, **Collins R**, Appleby P, Parish S, Sleight P, Peto R on behalf of the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. *BMJ* 1998; 316: 1337-43

Danesh J, **Collins R**, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. *JAMA* 1998; 279: 1477-82

Homocysteine Lowering Trialists' Collaboration (writing committee: Clarke R, Frost C, Leroy V, **Collins R**). Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. *BMJ* 1998; 316: 894-98

Early Breast Cancer Trialists' Collaborative Group (writing committee: Clarke M, **Collins R**, Davies C, Godwin J, Gray R, Peto R). Tamoxifen for early breast cancer: an overview of the randomised trials. *Lancet* 1998; 351: 1451-67

Early Breast Cancer Trialists' Collaborative Group (writing committee: Clarke M, **Collins R**, Davies C, Godwin J, Gray R, Peto R). Polychemotherapy for early breast cancer: an overview of the randomised trials. *Lancet* 1998; 352: 930-42

Neal B, Clark T, MacMahon S, Rodgers A, Baigent C, **Collins R** on behalf of the Anti-thrombotic Trialists' (ATT) Collaboration. Blood pressure and the risk of recurrent vascular disease. *Am J Hypertension* 1998; 11: 25A-26A

Clarke R, Breeze E, Sherliker P, Shipley M, Youngman L, Fletcher A, Fuhrer R, Leon D, Parish S, **Collins R**, Marmot M. Design, objectives, and lessons from a pilot 25 year follow up re-survey of survivors in the Whitehall study of London Civil Servants. *J Epidemiol & Com Health* 1998; 52: 364-69

ACE-inhibitor Myocardial Infarction Collaborative Group (writing committee: Franzosi MG, Santoro E, Zuanetti G, Baigent C, **Collins R** et al). Indications for ACE-inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. *Circulation* 1998; 97: 2202-12

World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration (writing committee: MacMahon S, Neal A, Rodgers A, Baigent C, **Collins R**). Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. *J Hypertension* 1998; 16: 127-37

Clarke R, **Collins R**. Can dietary supplements with folic acid or vitamin B₆ reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. *J Cardiovasc Risk* 1998; 5: 249-55

Collins R, Malacrida R, Moccetti T. Comparison of the early outcome of acute myocardial infarction in women and men. *N Engl J Med* 1998; 338: 1544 (letter)

1999

MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. *Eur Heart J* 1999; 20: 725-41

Baigent C, Chen Z, **Collins R**, Peto R, Sudlow C. Immediate aspirin for suspected ischaemic stroke. *Lancet* 1999; 353: 151-52 (letter)

Baigent C, **Collins R**, Peto R. Large-scale randomized trials. In: Hennekens CH (ed). *Clinical Trials in Cardiovascular Disease*. W B Saunders, 1999, pp.24-30

Baigent C, **Collins R**. Aspirin and heparin. In: Hennekens CH (ed). *Clinical Trials in Cardiovascular Disease*. W B Saunders, 1999, pp.55-64

Baigent C, **Collins R**. Thrombolytic therapy. In: Hennekens CH (ed). *Clinical Trials in Cardiovascular Disease*. W B Saunders, 1999, pp.65-75

HIV Trialists' Collaborative Group (writing committee: Darbyshire J, Babiker A, Walker S, **Collins R**, Peto R). Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. *Lancet* 1999; 353: 2014-25

Clarke R, Shipley M, Lewington S, Youngman L, **Collins R**, Marmot M, Peto R. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. *Am J Epidemiol* 1999; 150: 341-53

Danesh J, Youngman L, Clark S, Parish S, Peto R, **Collins R** for the International Studies of Infarct Survival (ISIS) Collaborative Group. *Helicobacter pylori* infection and early onset myocardial infarction: case-control and sibling pairs study. *BMJ* 1999; 319: 1157-62

Danesh J, Koreth J, Youngman L, **Collins R**, Arnold JR, Balarajan Y, McGee J, Roskell D. Is *Helicobacter pylori* a factor in coronary atherosclerosis? *J Clin Microbiol* 1999; 37: 1651

Prospective Studies Collaboration (writing committee: Lewington S, MacMahon S, Clarke R, **Collins R**, Duffy S, Qizilbash N, Rodgers A, Peto R). Collaborative overview ("meta-analysis") of prospective observational studies of the associations of usual blood pressure and usual cholesterol levels with common causes of death: protocol for the second cycle of the Prospective Studies Collaboration. *J Cardiovasc Risk* 1999; 6: 315-20

Peto R, **Collins R**. Better patency with SK than with tPA? *J Am Coll Cardiol* 1999; 33: 287-88 (letter)

2000

Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delépine M, Lathrop M, Peto R, **Collins R** for the International Studies of Infarct Survival (ISIS) Collaborators. Large-scale test of hypothesised associations between the angiotensin converting enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. *Lancet* 2000; 355: 434-42

Danesh J, **Collins R**, Peto R, Lowe GDO. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. *Eur Heart J* 2000; 21: 515-20

Pulmonary Embolism Prevention (PEP) Trial Collaborative Group (writing committee: Rodgers A, MacMahon S, **Collins R**, Prentice C). Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet* 2000; 355: 1295-1302

Collins R, Rodgers A, Prentice C, MacMahon S on behalf of the PEP Trial Collaborative Group. PEP trial. *Lancet* 2000; 356: 250-51 (letter)

Early Breast Cancer Trialists' Collaborative Group (writing committee: Clarke M, **Collins R**, Davies C, Godwin J, Gray R, Peto R). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. *Lancet* 2000; 355: 1757-70

Danesh J, Lawrence M, Murphy M, Roberts S, **Collins R**. Systematic review of the epidemiological evidence on *Helicobacter pylori* infection and nonulcer or uninvestigated dyspepsia. Arch Intern Med 2000; 160: 1192-98

Chen ZM, Sandercock P, Pan HC, Counsell C, **Collins R**, Liu LS, Xie JX, Warlow C, Peto R, on behalf of the CAST and IST collaborative groups. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 2000; 31: 1240-49

Chen Z, Xu Z, **Collins R**, Li WX, Peto R. Smoking and mortality in China: a prospective study of 9351 middle-aged adults in Shanghai, with a 16-year follow-up. In: Lu R, Mackay J, Niu S, Peto R (eds). Tobacco: The Growing Epidemic. Springer Verlag, London, 2000, pp.84-90

Armitage J, **Collins R**. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials (editorial). Heart 2000; 84: 357-60

Clarke R, Breeze E, Youngman L, Sherliker P, Bell P, Shah S, Shipley M, **Collins R**, Leon D, Marmot M, Fletcher A. Re-survey of the Whitehall study of London civil servants: changes in risk factors for cardiovascular disease during 29 years of follow-up. J Cardiovasc Risk 2000; 7: 251-57

Danesh J, **Collins R**, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000; 102: 1082-85

Latini R, Tognoni G, Maggioni AP, Baigent C, Braunwald E, Chen Z-M, **Collins R**, Flather M, Franzosi MG, Kjekshus J, Køber L, Liu L-S, Peto R, Pfeffer M, Pizzetti F, Santoro E, Sleight P, Swedberg K, Tavazzi L, Wang W, Yusuf S, on behalf of the Angiotensin-converting Enzyme inhibitor Myocardial Infarction Collaborative Group. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. J Am Coll Cardiol 2000; 35: 1801-07

Second Chinese Cardiac Study (CCS-2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. J Cardiovasc Risk 2000; 7: 435-41

2001

Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001; 357: 373-80

MacMahon S, **Collins R**. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001; 357: 455-62

Danesh J, **Collins R**. Antibiotics in the prevention of coronary heart disease: review of the randomised trials. In: Mehta JL (ed). Inflammatory and Infectious Basis of Atherosclerosis. Birkhäuser Verlag, Basel, 2001, pp.237-42

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, **Collins R**, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial. J Hypertens 2001; 19: 1-8

Ridker PM, Danesh J, Youngman L, **Collins R**, Stampfer M, Peto R, Hennekens CH. A prospective study of *Helicobacter pylori* seropositivity and the risk for future myocardial infarction among socioeconomically similar US men. Ann Intern Med 2001; 135: 184-88

Baigent C, **Collins R**, Peto R. Benefit of aspirin plus ACE inhibitor (letter). Am J Cardiol 2001; 37: 1474-75

Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer (Cochrane Review). In: The Cochrane Library, Issue 1, 2001. Oxford: Update software

The ASCOT Steering Committee: Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, **Collins R**, Kjeldsen SE, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. *J Human Hypertension* 2001; 15 (Suppl 1): S11-S12

2002

Antithrombotic Trialists' (ATT) Collaboration (writing committee: C Baigent, C Sudlow, **R Collins**, R Peto). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. *BMJ* 2002; 324: 71-86

Heart Protection Study Collaborative Group (writing committee: **Collins R**, Armitage J, Parish S, Sleight P, Peto R). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360: 7-22

Heart Protection Study Collaborative Group (writing committee: **Collins R**, Armitage J, Parish S, Sleight P, Peto R). MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360: 23-33

Clarke R, Lewington S, Youngman L, Sherliker P, Peto R, **Collins R**. Under-estimation of the importance of blood pressure and cholesterol for coronary heart disease mortality in old age. *Eur Heart J* 2002; 23: 286-93

Youngman LD, Clark S, Manley S, Peto R, **Collins R**. Reliable measurement of glycosylated hemoglobin in frozen blood samples: implications for epidemiologic studies. *Clin Chem* 2002; 48: 1627-29

Bonnici F, Keavney B, **Collins R**, Danesh J. Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies. *BMJ* 2002; 325: 517-19

Huxley R, Neil A, **Collins R**. Unravelling the "fetal origins" hypothesis: is there really an inverse association between birth weight and subsequent blood pressure? *Lancet* 2002; 360: 659-65

Teo KK, Yusuf S, Pfeffer M, Kober L, Hall A, Pogue J, Latini R, **Collins R**, for the ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. *Lancet* 2002; 360: 1033-43

Homocysteine Studies Collaboration (writing committee: Clarke R, Lewington S, Donald A, **Collins R**). Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA* 2002; 288: 2015-22

Collins R, Armitage J. High-risk elderly patients PROSPER from cholesterol-lowering therapy. *Lancet* 2002; 360: 1618-19

Prospective Studies Collaboration (writing committee: Lewington S, Clarke R, Qizilbash N, Peto R, **Collins R**). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; 360: 1903-13

Huxley R, Neil A, **Collins R**. Unravelling the fetal origins hypothesis (Authors' reply). *Lancet* 2002; 360: 2074-75

Collins R, Armitage J, Parish S, Sleight P, Peto R, for the MRC/BHF Heart Protection Study. MRC/BHF Heart Protection Study (Authors' reply). *Lancet* 2002; 360:1783-84

2003

Heart Protection Study Collaborative Group (writing committee: **Collins R**, Armitage J, Parish S, Sleight P, Peto R). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003; 361: 2005-16

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, **Collins R**, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Östergren J, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; 361: 1149-58

Clark S, Youngman LD, Palmer A, Parish S, Peto R, **Collins R**. Stability of plasma analytes after delayed separation of whole blood: implications for epidemiological studies. *Int J Epidemiol* 2003; 32: 125-30

Clark S, Youngman LD, Sullivan J, Peto R, **Collins R**. Stabilization of homocysteine in unseparated blood over several days: a solution for epidemiological studies. *Clin Chem* 2003; 49: 518-20

Keavney B, Parish S, Palmer A, Clark S, Youngman L, Danesh J, McKenzie C, Delépine M, Lathrop M, Peto R, **Collins R**, for the International Studies of Infarct Survival (ISIS) Collaborators. Large-scale evidence that the cardiotoxicity of smoking is not significantly modified by the apolipoprotein E genotype. *Lancet* 2003; 361: 396-98

Lewington S, Clarke R, Qizilbash N, Peto R, **Collins R**, on behalf of the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality. (Authors' reply) *Lancet* 2003; 361: 1391-92

Collins R, Armitage J, Parish S, Sleight P, Peto R, for the MRC/BHF Heart Protection Study. MRC/BHF Heart Protection Study (Authors' reply) *Lancet* 2003; 361: 529-30

Collins R, Armitage J, Parish S, Sleight P, Peto R on behalf of the MRC/BHF Heart Protection Study Collaborative Group. Comments on the MRC/BHF Heart Protection Study (Authors' reply). *Lancet* 2003; 362: 744-45

Keavney B, Parish S, Lathrop M, Peto R, **Collins R**. In search of genetic precision (Authors' reply). *Lancet* 2003; 361: 1909-10

Collins R, Peto R, Gray R, Parish S. Large-scale randomized evidence: trials and overviews. In: *Oxford Textbook of Medicine*, 4th edition (eds DA Warrell, TM Cox, JD Firth, EJ Benz). Oxford: Oxford University Press, 2003

2004

International Artemisinin Study Group (chair of Advisory Group) Artesunate combinations for treatment of malaria: meta-analysis. *Lancet* 2004; 363: 9-17

Wheeler JG, Keavney B, Watkins H, **Collins R**, Danesh J. Four paraoxonase gene polymorphisms in 11000 cases of coronary heart disease and 13000 controls: meta-analysis of 43 studies. *Lancet* 2004; 363: 689-95

Heart Protection Collaborative Group (writing committee: **Collins R**, Armitage J, Parish S, Sleight P, Peto R). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. *Lancet* 2004; 363: 757-67

Clark S, Youngman LD, Chukwurah B, Palmer A, Parish S, Peto R, **Collins R**. Effect of temperature and light on the stability of fat-soluble vitamins in whole blood over several days: implications for epidemiological studies. *Int J Epidemiol* 2004; 33: 1-8

Collins R, Armitage J, Parish S, Sleight P, Peto R for the MRC/BHF Heart Protection Study Collaborative Group. New analyses of Heart Protection Study (Authors' reply). *Lancet* 2004; 363: 1828

PROCARDIS Consortium (principal investigators: Watkins H, **Collins R**, Tognoni G, Hansten A, Assmann G): A trio family study showing association of the lymphotoxin- α N26 (804A) allele with coronary artery disease. *Eur J Hum Genetics* 2004; 12: 770-774

Keavney B, Palmer A, Parish S, Clark S, Youngman L, Danesh J, McKenzie C, Delépine M, Lathrop M, Peto R, **Collins R**, for the International Studies of Infarct Survival (ISIS) Collaborators. Lipid-related genes and myocardial infarction in 4685 cases and 3460 controls: discrepancies between genotype, blood lipid concentrations and coronary disease risk. *Int J Epidemiol* 2004; 33: 1-12

Huxley R, Owen CG, Whincup PH, Cook DG, Colman S, **Collins R**. Birth weight and subsequent cholesterol levels: exploration of the "Fetal Origins" hypothesis. *JAMA* 2004; 292: 2755-64

2005

Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, Cairns HS, **Collins R**, Foley RN, Frighi V, Kourellias K, Ratcliffe PJ, Rogerson M, Scoble JE, Tomson CRV, Warwick G, Wheeler DC. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. *Am J Kid Dis* 2005; 45: 473-84

Heart Protection Study Collaborative Group (writing committee: Armitage J, **Collins R**, Bowman L, Parish S, Sleight P, Peto R). The effects of cholesterol-lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial. *BMC Medicine* 2005; 3:6 www.biomedcentral.com/1741-7015/3/6

Heart Protection Study Collaborative Group (writing committee: Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, **Collins R**). Cost-effectiveness of simvastatin in people at different levels of cardiovascular disease risk: economic analysis of a randomised trial in 20,536 individuals. *Lancet* 2005; 365: 1779-85

Cholesterol Treatment Trialists' (CTT) Collaborators (writing committee: Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, **Collins R**, Simes J). Efficacy and safety of cholesterol-lowering treatment: meta-analysis of individual data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005; 366: 1267-78

COMMIT collaborative group (writing committee: Chen ZM, Pan HC, Chen YP, Peto R and **Collins R**). Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet* 2005; 366: 1607-21

COMMIT collaborative group (writing committee: Chen ZM, Xie J, Chen YP, Jiang L, Pan HC, Peto R, Liu L, **Collins R**). Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet* 2005; 366: 1622-32

Fairbank J, Frost H, Wilson-MacDonald J, Yu L-M, Barker K, **Collins R**, for the Spine Stabilisation Trial Group. Randomised controlled trial to compare surgical stabilisation of the lumbar spine with an intensive rehabilitation programme for patients with chronic low back pain: the MRC Spine Stabilisation Trial. *BMJ* 2005; 330:1233-9

Early Breast Cancer Trialists' Collaborative Group (writing committee: Clarke M, **Collins R**, Darby S, Davies C, Evans V, Godwin J, Gray R, McGale P, Peto R, Wang Y). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005; 365: 1687-1717

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (writing committee: Clarke M, **Collins R**, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005; 366: 2087-2106

Sever PS, Poulter NR, Dahlöf B, Wedel H, Beevers G, Caulfield M, **Collins R**, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT investigators. The

Anglo-Scandinavian Cardiac Outcomes Trial- Lipid-Lowering Arm (ASCOT-LLA): Reduction in cardiovascular events with atorvastatin in 2532 patients with type 2 diabetes. *Diabetes Care* 2005; 28:1151-57

Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, **Collins R**, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Östergren J, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005; 366: 895-906

Chen Z, Lee L, Chen J, **Collins R**, Wu F, Guo Y, Linksted P, Peto R. Cohort Profile: The Kadoorie study of chronic disease in China (KSCDC). *Int J Epidemiol* 2005; 34: 1243-49

Fibrinogen Studies Collaboration (writing committee: Danesh J, Lewington S, Thompson SG, Lowe DGO, **Collins R**). Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. *JAMA* 2005; 294: 1799-1809

Homocysteine Lowering Trialists' Collaboration (writing committee: Clarke R, Frost C, Sherliker P, Lewington S, **Collins R**). Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. *Am J Clin Nutr* 2005; 82: 806-12

Roderick P, Ferris G, Wilson K, Halls H, Jackson D, **Collins R**, Baigent C. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. *Health Technology Assessment* 2005; 9(49): 1-76

2006

B-Vitamin Treatment Trialists' Collaboration (writing committee: Clarke R, Armitage J, Lewington S, Sherliker P, **Collins R**) Homocysteine-lowering trials for prevention of cardiovascular events: A review of the design and power of the large randomized trials. *Am Heart J* 2006; 151: 282-7

Academy of Medical Sciences Working Group (writing committee: Chalmers S, **Collins R**, Luker K, Newton J, Silman A, Souhami R, Watt G, Wessely S, Zimmern R) Personal data for public good: using health information in medical research: A Report from the Academy of Medical Sciences. *Acad Med Sci* January 2006

Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, Ball S, Baxter A, Blackwell L, Cairns HS, Carr S, **Collins R**, Kourellias K, Rogerson M, Scoble JE, Tomson CRV, Warwick G, Wheeler DC. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. *Am J Kid Dis* 2006; 47: 385-95

Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, **Collins R**, Danesh J. Seven haemostatic gene polymorphisms in 64,155 cases and 91,307 controls. *Lancet* 2006; 367:651-8

Chen Z, Yang G, Zhou M, Smith M, Offer A, Ma J, Wang L, Pan H, Whitlock G, **Collins R**, Niu S, Peto R. Body mass index and mortality from ischaemic heart disease in a lean population: 10 year prospective study of 220,000 adult men. *Int J Epidemiol* 2006; 35: 141-150.

Tapia-Conyer R, Kuri-Morales P, Alegre-Diaz J, Whitlock G, Emberson J, Clark S, Peto R, **Collins R**. Cohort profile: The Mexico City Prospective Study. *Int J Epidemiol* 2006; 35: 243-49.

Chen Z, **Collins R**, Peto R, Xie J, Jiang L, Liu L. Clopidogrel and metoprolol in myocardial infarction. (Authors' reply) *Lancet* 2006; 367: 813.

Farrall M, Green FR, Peden JF, Olsson PG, Clarke R, Hellenius M-L, Rust S, Lagercrantz J, Franzosi MG, Schulte H, Carey A, Olsson GO, Assmann G, Tognoni G, **Collins R**, Hamsten A, Watkins H on

behalf of the PROCARDIS Consortium. Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. *PLoS Genetics* 2006; 2: 755-61.

Clarke R, Xu P, Bennett D, Lewington S, Zondervan K, Parish S, Palmer A, Clark S, Cardon L, Peto R, Lathrop M, **Collins R** for the International Study of Infarct Survival (ISIS) Collaborators. Lymphotoxin- α gene and risk of myocardial infarction in 6928 cases and 2712 controls in the ISIS case-control study. *PLoS Genetics* 2006; 2; e107, 990-96

Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, Delépine M, Lathrop M, Peto R, **Collins R**, for The International Studies of Infarct Survival (ISIS) Collaborators. Fibrinogen and coronary heart disease: test of causality by "Mendelian randomisation". *Int J Epidemiol* 2006; 35: 935-43

Davies C, **Collins R**. Balancing potential risks and benefits of using confidential data. *BMJ* 2006, 333: 349-51

Heart Protection Study Collaborative Group (writing committee: Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, **Collins R**). Lifetime cost-effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. *BMJ*. 2006; 333: 1145

2007

Barlera S, Specchia C, Farrall M, Chiodini BD, Franzosi MG, Rust S, Green F, Nicolis EB, Peden J, Assmann G, Collins R, Hamsten A, Tognoni G, Watkins H on behalf of the PROCARDIS Consortium. Multiple QTL influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS study. *Eur J Hum Genet*. 2007; 15: 221-7

Heart Protection Study Collaborative Group (writing committee: Emberson Jr, Ng LL, Armitage J, Bowman L, Parish S, **Collins R**). N-terminal pro-B-type natriuretic peptide, vascular disease risk and cholesterol reduction among 20,536 patients in the MRC/BHF Heart Protection Study. *JACC* 2007; 49: 311-9

Clarke R, Shipley M, Breeze E, **Collins R**, Marmot M, Halsey J, Fletcher A, Hemingway H. Survival in relation to angina symptoms and diagnosis among men aged 70-90 years: the Whitehall Study. *Eur J Cardiovasc Prev Rehabil* 2007; 14:280-86

Clarke R, Emberson JR, Parish S, Palmer A, Shipley M, Linksted P, Sherliker P, Clark S, Armitage A, Fletcher A, **Collins R**. Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men. *Arch Intern Med* 2007; 167: 1373-78

Collins R, MacMahon S. Reliable assessment of the effects of treatments on mortality and major morbidity. In: *THE LANCET Treating individuals: from randomised trials to personalized medicine*. pp.3-35 (ed. Rothwell, PM) Elsevier, 2007

Heart Protection Study Collaborative Group (writing committee: Bulbulia R, Armitage J, Bowman L, Parish S, **Collins R**) Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular outcomes in 20,536 people with peripheral arterial disease and other high risk conditions. *J Vasc Surg* 2007; 45: 645-54

Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U, Danesh J. Association of apolipoprotein E genotypes with lipid levels and coronary risk. *JAMA* 2007; 298: 1300-11

UK Clinical Research Collaboration (**R Collins**; member of simulation team). UKCRC R&D Advisory Group to Connecting for Health. Report of Research Simulations. 2007

B-Vitamin Treatment Trialists' Collaboration (Writing Committee: Clarke R, Armitage J, Lewington S, **Collins R**) Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis. *Clin Chem Lab Med* 2007; 45: 1575-81

Huxley R, Owen CG, Whincup PH, Cook DG, Rich-Edwards J, Davey Smith G, **Collins R**. Is birth weight a risk factor for ischemic heart disease in later life? *Am J Clin Nutr* 2007; 85: 1244-50

Prospective Studies Collaboration (Writing Committee: Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, **Collins R**). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. *Lancet* 2007; 370: 1829-39

SEARCH Study Collaborative Group (Writing committee: Bowman L, Armitage J, Bulbulia R, Parish S, **Collins R**). Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): Characteristics of a randomized trial among 12064 myocardial infarction survivors. *Am Heart J* 2007; 154: 815-23

2008

Willer CJ, Sanna D, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, Parish S, Shen H, Galan P, Meneton, P Herberg S, Zelenika D, Chen W-M, Li Y, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, **Collins R**, Bergman RN, Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, Schlessinger D, Mohlke KL, Abecasis GR. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nature Genet* 2008; 40: 161-69

Early Breast Cancer Trialists' Collaborative Group (Secretariat M Clarke, **R Collins**, S Darby, C Davies, P Elphinstone, V Evans, J Godwin, R Gray, C Hicks, S James, E MacKinnon, P McGale, T McHugh, R Peto, C Taylor, Y Wang). Adjuvant polychemotherapy in oestrogen-receptor-poor breast cancer: patient level meta-analysis of randomised trials. *Lancet* 2008; 371: 29-40

Specchia C, Barlera S, Chiodini B D, Nicolis E, Farrall M, Peden J, **Collins R**, Watkins H, Tognoni G, Franzosi MG on behalf of the PROCARDIS Consortium. Quantitative trait genetic linkage analysis of Body-Mass Index in familial coronary artery disease. *Human Heredity* 2008; 66: 19-24

Cholesterol Treatment Trialists' (CTT) Collaborators (Writing committee: Kearney PM, Blackwell L, **Collins R**, Keech A, Simes J, Peto R, Armitage J, Baigent C). Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008; 371: 117-25

Eisenstein EL, **Collins R**, Cracknell BS, Podesta O, Reid ED, Sandercock P, Shakhov Y, Terrin ML, Sellers MA, Califf RM, Granger CB, Diaz R. Sensible approaches for reducing clinical trial costs. *Clin Trials* 2008; 5: 75-84

Clarke R, Emberson JR, Breeze E, Casas JP, Parish S, Hingorani AD, Fletcher A, **Collins R**, Smeeth L. Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. *Eur Heart J* 2008; 29: 800-809

Yusuf S, Bosch J, Devereaux PJ, **Collins R**, Baigent C, Granger C, Califf R, Temple R. Sensible guidelines for the conduct of large randomized trials. *Clin Trials* 2008; 5: 38-39

Bennett DA, Xu P, Clarke R, Zondervan K, Parish S, Palmer A, Cardon L, Peto R, Lathrop M, **Collins R** for the International Study of Infarct Survival (ISIS) Collaborators. The exon 1-8C/G SNP in the PSMA6 gene contributes only a small amount to the burden of myocardial infarction in 6946 cases and 2720 controls from a United Kingdom population. *Eur J Hum Genet* 2008; 16: 480-86

Zhou M, Offer A, Yang G, Smith M, Hui G, Whitlock G, **Collins R**, Huang Z, Peto R, Chen Z. Body mass index, blood pressure and mortality from stroke: a nationally representative prospective study of 212 000 Chinese men. *Stroke* 2008; 39: 753-59

Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, Clarke R, **Collins R**, Franzosi MG, Tognoni G, Seedorf U, Rust S, Eriksson P, Hamsten A, Farrall M, Watkins H for the PROCARDIS

consortium. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. *Hum Mol Genet* 2008; 17: 806-14

Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, **Collins R**. Does simvastatin save lives; If so, when and in whom? (authors' reply). *J Vasc Surg*; 47: 901

Gray R, **Collins R**, Peto R, Wheatley K. Large-scale randomized evidence: trials and overviews. in: Price P, Sikora K, Illidge T (eds) *Treatment of Cancer*. Fifth Edition, Chapter 56, pp. 1338-51. Hodder Arnold: 2008

SEARCH Study Collaborative Group (Writing committee: Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, **Collins R**). *SLCO1B1* variants and statin-induced myopathy — A genomewide study. *N Engl J Med* 2008; 359: 789-99

Peto R, Emberson J, Landray M, Baigent C, **Collins R**, Clare R, Califf R. Analyses of cancer data from three Ezetimibe trials. *N Engl J Med* 2008; 359: 1357-66

Ostergren J, Poulter NR, Sever PS, Dahlof B, Wedel H, Beevers G, Caulfield M, **Collins R**, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, for the ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. *J Hypertens* 2008; 26: 2103-11

2009

Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, Ferrucci L, Scheet P, Sanna S, Uda M, Yang Q, Lunetta KL, Dupuis J, de Bakker PI, O'Donnell CJ, Chambers JC, Kooper JS, Hercberg S, Meneton P, Lakatta EG, Scuteri A, Schlessinger D, Tuomilehto J, Collins FS, Groop L, Altshuler D, **Collins R**, Lathrop GM, Melander O, Salomaa V, Peltonen L, Orho-Melander M, Ordovas JM, Boehnke M, Abecasis GR, Mohlke KL, Cupples LA. Common variants at 30 loci contribute to polygenic dyslipidemia. *Nat Genet*. 2009; 41: 56-65

Clarke R, Shipley M, Armitage J, **Collins R**, Harris W. Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servants. *Br J Nutr* 2009; 102: 279-84

Peto R, **Collins R**. Analyses of cancer data from three Ezetimibe trials. **Collins R**, Peto R (authors reply). *N Engl J Med* 2009; 360: 86-87

Kuri-Morales P, Emberson J, Alegre-Diaz J, Tapia-Conyer R, **Collins R**, Peto R, Whitlock G. The prevalence of chronic diseases and major disease risk factors at different ages among 150 000 men and women living in Mexico City: cross-sectional analyses of a prospective study. *BMC Public Health* 2009; 9: 9

MRC/BHF Heart Protection Study Collaborative Group (writing committee: Mihaylova B, Briggs A, Hlatky M, Armitage J, Parish S, Gray A, **Collins R**) Statin cost-effectiveness in the United States for people at different vascular risk levels. *Circ Cardiovasc Qual Outcomes* 2009; 2: 65-72

MRC/BHF Heart Protection Study Collaborative Group (writing committee: Armitage J, Bowman L, **Collins R**, Parish S, Tobert J) Effects of simvastatin 40mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. *BMC Clin Pharm* 2009; 9: 6

Prospective Studies Collaboration (writing committee: Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, **Collins R**, Peto R). Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet* 2009; 373: 1083-96

Antithrombotic Trialists' (ATT) Collaboration (writing committee: Baigent C, Blackwell L, **Collins R**, Emberson JR, Godwin J, Peto R; Buring JE, Hennekens CH, Kearney PM, Meade TW, Patrono C, Roncaglioni MC, Zanchetti A) Aspirin in the primary and secondary prevention of vascular disease:

collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009; 373: 1849-60

Newhouse S, Farrall M, Wallace C, Hoti M, Burke B, Howard P, Onipinla A, Lee K, Shaw-Hawkins S, Dobson R, Brown M, Samani NJ, Dominicczak AF, Connell JM, Lathrop GM, Kooner J, Chambers J, Elliott P, Clarke R, **Collins R**, Laan M, Org E, Juhanson P, Veldre Gudrun, Viigimaa M, Eyheramendy S, Cappuccio FP, Ji C, Iacone R, Strazzullo P, Kumari M, Marmot M, Brunner E, Caulfield M, Munroe PB. Polymorphisms in the *WNK1* gene are associated with blood pressure variation and urinary potassium excretion. *PLoS One* 2009; 4(4): e5003.

Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A, Whitlock G, Clark S, Youngman L, Sleight P, **Collins R** for the International Studies of Infarct Survival (ISIS) collaborators. The joint effects of apolipoprotein B, apolipoprotein A₁, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. *Eur Heart J* 2009; 30: 2137-46

Baigent C, Blackwell L, Emberson J, **Collins R**, Peto R, on behalf of the Antithrombotic Trialists' Collaboration. Aspirin in the primary prevention of vascular disease (Authors' reply). *Lancet* 2009; 374: 879

Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown IJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruukonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollenweider P, Waeber G, Jarvelin M-R, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, **Collins R**, Samani NJ, Watkins H, Kooner JS. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. *JAMA* 2009; 302: 37-48

Emerging Risk Factors Collaboration (writing committee: Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, **Collins R**, Thompson SG, Danesh J). Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA* 2009; 302: 412-23

Paré G, Chasman DI, Parker AN, Zee RR, Mälarstig A, Seedorf U, **Collins R**, Watkins H, Hamsten A, Miletich JP, Ridker PM. Novel associations of *CPS1*, *MUT*, *NOX4*, and *DPEP1* with plasma homocysteine in a healthy population: a genome-wide evaluation of 13 974 participants in the Women's Genome Health Study. *Circ Cardiovasc Genet.* 2009; 2:142-50.

The Emerging Risk factors Collaboration. (writing committee: Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, **Collins R**, Thompson SG, Danesh J). Major lipids, apolipoproteins, and risk of vascular disease. *JAMA* 2009; 302: 1993-2000

Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, **Collins R**, Watkins H, Farrall M on behalf of the PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med* 2009; 361: 2518-28

2010

The Emerging Risk Factors Collaboration. (writing committee: Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, **Collins R**, Danesh J). C-reactive protein concentration and the risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* 2010; 375: 132-40

The Lp-PLA2 Studies Collaboration. (writing committee: Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Cushman M, Hofman A, Packard C, Thompson SG, **Collins R**, Danesh J). Lipoprotein-associated phospholipase A₂ and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. *Lancet* 2010; 375:1536-44

SEARCH Collaborative Group (writing committee: Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, **Collins R**). Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. *JAMA* 2010; 303(24):2486-94

Baigent C, Peto R, Gray R, Parish S, **Collins R**. Large-scale randomized evidence: trials and meta-analyses of trials. In: Warrell DA et al (eds), *Oxford Textbook of Medicine*, 5th edition, 2010

B-Vitamin Treatment Trialists' Collaboration (writing committee: Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, Bønaa KH, Spence JD, Nygård O, Jamison R, Gaziano JM, Guarino P, Bennett D, Mir F, Peto R, **Collins R**). Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Meta-analysis of 8 randomized trials involving 37,485 individuals. *Arch Intern Med* 2010; 170: 1622-31

Cholesterol Treatment Trialists' (CTT) Collaboration. (writing committee: Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, Peto R, Barnes EH, Keech A, Simes J, **Collins R**). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010; 376: 1670-81

SEARCH Collaborative Group (writing committee: Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, **Collins R**). Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. *Lancet* 2010; 376: 1658-69

Manolio TGA, **Collins R**. Enhancing the feasibility of large cohort studies. *JAMA* 2010; 304: 2290-91

SHARP Collaborative Group (writing committee: Baigent C, Landray M, Reith C, Dasgupta T, Emberson J, Herrington W, Lewis D, Mafham M, **Collins R**). Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *Am Heart J* 2010; 160: 785-794

Heart Protection Study Collaborative Group (writing committee: Parish S, Offer A, Thompson A, Link E, Di Angelantonio E, Bowman L, Armitage J, Danesh J, **Collins R**). Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality. *J Intern Med* 2010 268:348-58

2011

Academy of Medical Sciences Working Group (writing committee: Rawlins M, Ashby D, Baker M, **Collins R**, Darbyshire J, Dezateux C, Evans S, Farrar M, Ford G, Gillen D, Johnson P, Kapur S, Kerr R, Knowles J, Parker M, Richardson G, Storrie P, Vallance P, Webb D). A new pathway for the regulation and governance of health research: A Report from the Academy of Medical Sciences. *Acad Med Sci* January 2011

Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, **Collins R**, on behalf of the Heart Protection Study Collaboration. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease, but not with stroke risk in the Heart Protection Study. *Circulation: Cardiovascular Genetics* 2011; 4: 68-73

MRC/BHF Heart Protection Study Collaborative Group (writing committee: Emberson J, Bennett D, Link E, Parish S, Danesh J, Armitage J, **Collins R**). C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study. *Lancet* 2011 377: 469-76.

Coronary Artery Disease (C4D) Genetics Consortium (writing committee: Peden JF, Hopewell JC, Saleheen D, Chambers JC, Hager J, Soranzo N, **Collins R**, Danesh J, Elliott P, Farrall M, Stirrups K, Zhang W, Hamsten A, Parish S, Lathrop M, Watkins H, Clarke R, Deloukas P, Kooner JS). A genome-wide association study in Europeans and South Asians reveals five novel loci for coronary artery disease. *Nat Genet* 2011; 43: 339-44

Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, **Collins R**, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med* 2011; 364: 829-41

The Emerging Risk Factors Collaboration (writing committee: Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, Sarwar N, Kizer JR, Lawlor DA, Nordestgaard BG, Ridker P, Salomaa V, Stevens J, Woodward M, Sattar N, **Collins R**, Thompson SG, Whitlock G, Danesh J. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. *Lancet* 2011: 377; 1085-95

MRC/BHF Heart Protection Study Collaboration (writing committee: Hopewell JC, Parish S, Clarke R, Armitage J, Bowman L, Hager J, Lathrop M, **Collins R**). No impact of *KIF6* genotype on vascular risk and statin response among 18,348 randomized patients in the Heart Protection Study. *JACC* 2011; 57: 2000-7

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, **Collins R**; on behalf of the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. 2011; 377: 2181-92

Chen Z, Chen J, **Collins R**, Guo Y, Peto R, Wu F, Li L on behalf of the China Kadoorie Biobank (CKB) collaborative group. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. *Int J Epidemiol* 2011; 1-15.

Chen Y, Jiang L, Smith M, Xie J, Pan H, **Collins R**, Liu L, Peto R, Chen Z for the Commit/CCS-2 collaborative group. Sex differences in hospital mortality following acute myocardial infarction in China: findings from a study of 45,852 patients in COMMIT/CCS-2 study. *Heart Asia*. 2011; 3(1): 104-110

IBC 50K CAD Consortium. Large scale gene-centric analysis identifies novel variants for coronary artery disease. *PLoS Genet* 2011 7(9): e1002260. doi:10.1371/journal.pgen.1002260

Heart Protection Study Collaborative Group (writing committee: Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, **Collins R**). Effects on 11 year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals. *Lancet* 2011: 378; 2013-2020

CTT Collaboration. (Writing committee: Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, **Collins R**, Simes J, Baigent C) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS ONE* 2012; 7: e29849. doi:10.1371/journal.pone.0029849

Li L-M, Jun LV, Guo Y, **Collins R**, Chen J-S, Peto R, Wu F, Chen Z-M, on behalf of The China Kadoorie Biobank Investigation Group. The China Kadoorie Biobank: related methodology and baseline characteristics of the participants. *Chin J Epidemiol*, 2012, 33, 249-55

Clarke R, Bennett DA, Parish S, Verhoef P, Dötsch-Klerk M, Lathrop M, Xu P, Nordestgaard BG, Holm H, Hopewell JC, Saleheen D, Tanaka T, Anand SS, Chambers JC, Kleber ME, Ouwehand WH, Yamada Y, Elbers C, Peters B, Stewart AFR, Reilly MM, Thorand B, Yusuf S, Engert JC, Assimes TL, Kooner J, Danesh J, Watkins H, Samani NJ, **Collins R**, Peto R, for the *MTHFR* Studies Collaborative Group. Homocysteine and coronary heart disease: meta-analysis of *MTHFR* case-control studies, avoiding publication bias. *PlosMed* 2012; 9: e1001177 (doi 10.1371/journal.pmed.1001177)

Manolio TA, Weis BK, Cowie CC, Hoover RN, Hudson K, Kramer BS, Berg C, **Collins R**, Ewart W, Gaziano JM, Hirschfeld S, Marcus PM, Masys D, McCarty CA, McLaughlin J, Patel AV, Peakman T, Pedersen NL, Schaefer C, Scott JA, Sprosen T, Walport M, Collins FS. New models for large prospective studies: Is there a better way? *Am J Epidemiol* 2012; 175: 859-66

Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, Gallacher J, Green J, Matthews P, Pell J, Sprosen T, **Collins R**, on behalf of UK Biobank. UK Biobank: Current status and what it means for epidemiology. *Health Policy & Technology* 2012; 1: 123-126

Lewington S, Li L, Sherliker P, Guo Y, Millwood I, Bian Z, Whitlock G, Yang L, **Collins R**, Chen J, Wu X, Wang S, Hu Y, Jiang L, Yang L, Lacey B, Peto R, Chen Z. Seasonal variation in blood pressure and its relationship with outdoor temperature in 10 diverse regions of China: the China Kadoorie Biobank. *J Hypertens* 2012; 30:1383-91

Cholesterol Treatment Trialists' (CTT) Collaboration. (writing committee: Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, **Collins R**, Baigent C) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012; 380: 581-90

Collins R. What makes UK Biobank special? Comment. *Lancet* 2012; 379: 1173-4

Heart Protection Study Collaborative Group (Writing Committee: Parish S, Offer A, Clarke R, Hopewell J, Hill M, Otvos JD, Armitage J, **Collins R**). Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. *Circulation* 2012; 125: 2469-78

Huang J; Sabater-Lleal M, Asselbergs FW, Tregouet D, Shin S-Y, Ding J, Baumert J, Oudot-Mellakh T, Folkersen L, Johnson AD, Smith NL, Williams SM, Ikram MA, Kleber ME, Becker DM, Truong V, Mychaleckyj JC, Tang W, Yang Q, Sennblad B, Moore JH, Williams FMK, Dehghan A, Silbernagel G, Schrijvers EMC, Smith S, Karakas M, Tofler GH, Silveira A, Navis GJ, Lohman K, Chen M-H, Peters A, Goel A, Hopewell JC, Chambers JC, Saleheen D, Lundmark P, Psaty BM, Strawbridge RJ, Boehm BO, Carter AM, Meisinger C, Peden JF, Bis JC, McKnight B, Öhrvik J, Taylor K, Franzosi MG, Seedorf U, **Collins R**, Franco-Cereceda A, Syvänen A-C, Goodall AH, Yanek LR, Cushman M, Müller-Nurasyid M, Folsom AR, Basu S, Matijevic N, van Gilst WK, Kooner JS, Hofman A, Danesh J, Clarke R, Meigs JB, DIAGRAM Consortium; Kathiresan S, Reilly MP, CARDIoGRAM Consortium, Klopp N, Harris TB, Winkelmann BR, Grant PJ, Hillege HL, Watkins H, C4D Consortium, Spector TD; Becker LC; Tracy RP, März W; Uitterlinden AG, Eriksson P, Cambien F, CARDIOGENICS Consortium, Morange P-E, Koenig W, Soranzo N, van der Harst P, Liu Y, O'Donnell CJ, Hamsten A. Genome-wide association study for circulating levels of plasminogen activator inhibitor-1 (PAI-1) provides novel insights into the regulation of PAI-1. *Blood* 2012; 120: 4873-81

Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, Armitage J, Manson JE, Hankey GJ, Spence JD, Galan P, Børnaa KH, Jamison R, Gaziano JM, Guarino P, Baron JA, Logan RFA,

Giovannucci EL, den Heijer M, Ueland PM, Bennett D, **Collins R**, Peto R, for the B-Vitamin Treatment Trialists' Collaboration. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. *Lancet* 2012 381:1029-36

2013

Millwood IY, Li L, Smith M, Guo Y, Yang L, Bian Z, Lewington S, Whitlock G, Sherliker P, **Collins R**, Chen J, Peto R, Wang H, Xu J, He J, Yu M, Liu H, Chen Z; China Kadoorie Biobank collaborative group. Alcohol consumption in 0.5 million people from 10 diverse regions of China: prevalence, patterns and socio-demographic and health-related correlates. *Int J Epidemiol* 2013, 42(3): 816-827

Hopewell JC, Parish S, Offer A, Link E, Clarke R, Lathrop M, Armitage J, **Collins R**, on behalf of the MRC/BHF Heart Protection Study Collaborative Group. Impact of common genetic variation on response to simvastatin therapy among 18,705 participants in the Heart Protection Study. *Eur Heart J* 2013; 34: 982-92

Davies C, Pan HC, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar V H, Badran A, Bonfill X, Bradbury J, Clarke M, **Collins R**, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzalka L, Pienkowski T, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R, for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet* 2013; 381: 805-16

Tomson J, Emberson J, Hill M, Gordon A, Armitage J, Shipley M, **Collins R**, Clarke R. Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths. *Eur Heart J* 2013; 34: 1365-74

Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Reilly MP, **Collins R**, Kathiresan S, Hamsten A, Thorsteinsdottir U, Kooner JS, Danesh D, Palmer CNA, Roberts R, Watkins H, Schunkert H, Samani NJ, for CARDIoGRAMplusC4D Consortium. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nature Genet* 2013; 45: 25-33

Gallacher J, **Collins R**, Elliott P, Palmer S, Burton P, Mitchell C, John G, Lyons R. A platform for the remote conduct of gene-environment interaction studies. *PLoS Medicine* 2013; 8 e54331

Du H, Bennett D, Li L, Whitlock G, Guo Y, **Collins R**, Chen J, Bian Z, Hong L-S, Feng S, Chen X, Chen L, Zhou R, Mao E, Peto R, Chen Z, on behalf of the China Kadoorie Biobank Collaborative Group. Physical activity and sedentary leisure time and their associations with BMI, waist circumference, and percentage body fat in 0.5 million adults: the China Kadoorie Biobank study. *Am J Clin Nutr* 2013; 97: 487-96

HPS2-THRIVE Study Collaborative Group (Writing Committee: Haynes R, Jiang L, Hopewell JC, Li J, Chen F, Parish S, Landray MJ, **Collins R**, Armitage J. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. *Eur Heart J* 2013; 34: 1279-91

Petersen SE, Matthews PM, Bamberg F, Bluemke DA, Francis JM, Friedrich MG, Leeson P, Nagel E, Plein S, Rademakers FE, Young AA, Garratt S, Peakman T, Sellors J, **Collins R**, Neubauer S. Imaging in population science: cardiovascular magnetic resonance in 100,000 participants of UK Biobank – rationale, challenges and approaches. *J Cardiovasc Magn Res* 2013; 15: 46

Reith C, Landray M, Devereaux PJ, Bosch J, Granger CB, Baigent C, Califf RM, **Collins R**, Yusuf S. Randomized clinical trials — removing unnecessary obstacles. *New Engl J Med* 2013; 369: 1061-65

Harvey NC, Matthews P, **Collins R**, Cooper C, for the UK Biobank Musculoskeletal Advisory Group. Osteoporosis epidemiology in UK Biobank: a unique opportunity for international researchers. *Osteoporosis International* 2013; 24: 2903-5

Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D, Feng QP, Rieder MJ, Chen Y-D, Rotter JI, Ridker PM, Hopewell JC, Parish S, Armitage J, **Collins R**, Wilke RA, Nickerson DA, Stephens M, Krauss RM. A statin-dependent QTL for *GATM* expression is associated with statin-induced myopathy. *Nature* 2013; 502: 377-80

Mezuk B, Chen YP, Yu CQ, Guo Y, Bian Z, **Collins R**, Chen JS, Pang ZC, Wang HJ, Peto R, Que XS, Zhang H, Tan ZW, Kendler KS, Li LM, Chen ZM. Depression, anxiety, and prevalent diabetes in the Chinese population: Findings from the China Kadoorie Biobank of 0.5 million people. *J Psychosom Res* 2013; 75: 511-17

Zhang Q, Li L, Smith M, Guo Y, Whitlock G, Bian Z, Kurmi O, **Collins R**, Chen J, Lv S, Pang Z, Chen C, Chen N, Xiong Y, Peto R, Chen Z on behalf of the China Kadoorie Biobank study collaboration. Exhaled carbon monoxide and its associations with smoking, indoor household air pollution and chronic respiratory diseases among 512,000 Chinese adults. *Int J Epidemiol* 2013; 42: 1464-75

2014

Hopewell J, Seedorf U; Farrall M, Parish S, Kyriakou T, Goel A, Hamsten A, Collins R; Watkins H, Clarke R on behalf of the PROCARDIS Consortium. Impact of Lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. *J Intern Med* 2014; 276: 260-8

Lewington S, Li L, Murugasen S, Hong LS, Yang L, Guo Y, Bian Z, **Collins R**, Chen J, He H, Wu M, He T, Ren X, Meng J, Peto R, Chen Z; on behalf of the China Kadoorie Biobank study collaboration. Temporal trends of main reproductive characteristics in ten urban and rural regions of China: the China Kadoorie Biobank study of 300 000 women. *Int J Epidemiol* 2014; 43:1252-62

Chen Y, Li L, Zhang Q, Clarke R, Chen J, Guo Y, Bian Z, Pan X, Peto R, Tao R, Shi K, Collins R, Ma L, Sun H, Chen Z. Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank study of 0.5 million people. *Int J Cardiol* 2014; 172: 88-95

Allen NE, Sudlow C, Peakman T, **Collins R**. UK Biobank data: come and get it. (editorial) *Sci Transl Med* 2014; 6: 224

Smith M, Li L, Augustyn M, Kurmi O, Chen J, **Collins R**, Guo Y, Han Y, Qin J, Xu G, Wang J, Bian Z, Zhou G, Peto R, Chen Z on behalf of the China Kadoorie Biobank Collaborative Group. Prevalence and correlates of airflow obstruction in ~317,000 never smokers in China. *Eur Respir J* 2014; 44: 66-77

Bragg F, Lee LM, Smith M, Guy Y, Chen Y, Millwood I, Zheng B, Walters R, Chen J, Yang L, **Collins R**, Peto R, Chen Z on behalf of China Kadoorie Biobank study. Associations of blood glucose and prevalent diabetes with risk of cardiovascular disease in 500 000 adult Chinese: the China Kadoorie Biobank. *Diabetic Medicine* 2014; 31: 540-51

Kurmi OP, Li L, Smith M, Augustyn M, Chen J, **Collins R**, Guo Y, Han Y, Qin J, Xu G, Wang J, Bian Z, Zhou G, Davis K, Peto R, Chen Z, on behalf of the China Kadoorie Biobank Collaborative Group. Regional variations in the prevalence and misdiagnosis of air flow obstruction in China: baseline results from a prospective cohort of the China Kadoorie Biobank (CKB). *BMJ Open Respir Res.* 2014; 1:e000025

Collins R. Lack of adverse effect of statin therapy on common muscle-related adverse events. (Letter) *Eur J Prev Cardiol* 2015; 22: 1066

Clarke R, Bennett D, Parish S, Lewington S, Skeaff M, Eussen SJPM, Lewerin C, Stott DJ, Armitage J, Hankey GJ, Lonn E, Spence D, Galan P, de Groot LC, Halsey J, Dangour AD, **Collins R**, Grodstein F on behalf of the B-Vitamin Treatment Trialists' Collaboration. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. *Am J Clin Nutr* 2014; 100: 657-66

The HPS2-THRIVE Collaborative Group (Writing Committee: Landray M, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, **Collins R**, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med* 2014; 371: 203-12

Du H, Li M, Whitlock G, Bennett D, Guo Y, Bian Z, Chen J, Sherliker P, Huang Y, Zhang N, Zheng X, Li Z, Hu R, **Collins R**, Peto R, Chen Z on behalf of the China Kadoorie Biobank (CKB) collaborative group. Patterns and socio-demographic correlates of domain-specific physical activities and their associations with adiposity in China Kadoorie Biobank study. *BMC Public Health* 2014; 14: 826

2015

Chen Z, Peto R, Iona A, Guo Y, Chen Y, Bian Z, Yang L, Zhang W, Lu F, Chen J, **Collins R**, Li L, for the China Kadoorie Biobank Collaborative Group. Emerging tobacco-related cancer risks in China: A nationwide, prospective study of 0.5 million adults. *Cancer* 2015; 121(S17): 3097-106

Chen Z, Peto R, Zhou M, Iona A, Smith M, Yang L, Guo Y, Chen Y, Bian Z, Lancaster G, Sherliker P, Pang S, Wang H, Su H, Wu M, Wu X, Chen J, **Collins R**, Li L. Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies. *Lancet* 2015; 386: 1447-56

Chen Z, Smith M, Du H, Guo Y, Clarke R, Zheng B, **Collins R**, Chen J, Qian Y, Wang X, Chen X, Tian X, Wang X, Peto R, Li L, for the China Kadoorie Biobank Collaborative Group. Blood pressure in relation to general and central adiposity among 500 000 adult Chinese men and women. *Int J Epidemiol* 2015; 44(4): 1305-19

Collins R. Lack of adverse effect of statin therapy on common muscle-related adverse events. *Eur J Prev Cardiol* 2015; 22: 1066. (Letter)

Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, **Collins R**, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A, for the Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. *Lancet* 2015; 385: 1397-405

Kurmi OP, Li L, Wang J, Millwood IY, Chen J, **Collins R**, Guo Y, Bian Z, Li J, Chen B, Xie K, Jia W, Gao Y, Peto R, Chen Z, On behalf of the China Kadoorie Biobank Collaborative Group. COPD and its association with smoking in Mainland China: a cross-sectional analysis of 0.5 million men and women from ten diverse areas. *Int J Chron Obstruct Pulmon Dis* 2015; 10: 655-65

Nelson CP, Hamby SE, Saleheen D, Hopewell JC, Zeng L, Assimes TL, Kanoni S, Willenborg C, Burgess S, Amouyel P, Anand S, Blankenberg S, Boehm BO, Clarke RJ, **Collins R**, Dedoussis G, Farrall M, Franks PW, Groop L, Hall AS, Hamsten A, Hengstenberg C, Hovingh GK, Ingelsson E, Kathiresan S, Kee F, König IR, Kooner J, Lehtimäki T, März W, McPherson R, Metspalu A, Nieminen MS, O'Donnell CJ, Palmer CNA, Peters A, Perola M, Reilly MP, Ripatti S, Roberts R, Salomaa V, Shah SH, Schreiber S, Siegbahn A, Thorsteinsdottir U, Veronesi G, Wareham N, Willer CJ, Zalloua PA, Erdmann J, Deloukas P, Watkins H, Schunkert H, Danesh J, Thompson JR, Samani NJ, F.R.C.P. for the CARDIoGRAM+C4D Consortium. Genetically determined height and coronary artery disease. *N Engl J Med* 2015; 372: 1608-18

Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, **Collins R**. UK Biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 2015; 12: e1001779

Yang L, Li L, Lewington S, Guo Y, Sherliker P, Bian Z, **Collins R**, Peto R, Liu Y, Yang R, Zhang Y, Li G, Liu S, Chen Z, Chen J, Lancaster G, Yang X, Williams A, Smith M, Chang Y, Millwood I, Chen Y, Hou C, Tan Y, Zhou H, Pang Z, Wang S, Zhang Y, Zhang K, Liu S, Hou W, Zhao Z, Pang Z, Feng W, Wu S, Yang L, Han H, He H, Yu B, Pan X, Wang S, Wang H, Hao X, Chen C, Lin S, Zheng X, Hu X, Zhou M, Wu M, Tao R, Wang Y, Hu Y, Ma L, Zhou R, Xu G, Lu Y, Dong B, Chen N, Huang Y, Li M, Meng J, Gan Z, Xu J, Qing J, Wu X, Gao Y, Luo G, Que X, Chen X, Ge P, He J, Ren X, Zhang H, Mao E, Li G, Li Z,

He J, Lei Y, Wang X, Liu G, Zhu B, Zhou G, Feng S, Gao Y, He T, Jiang L, Qin J, Sun H, Liu L, Yu M, Chen Y, Hu R, Hu Z, Hu J, Qian Y, Wu Z, Wang C, Chen L, Liu W, Liu H, Long X, Xu X, Xiong Y, Tan Z, Xie X, Peng Y, Jia W. Outdoor temperature, blood pressure, and cardiovascular disease mortality among 23,000 individuals with diagnosed cardiovascular diseases from China. *Eur Heart J* 2015; 36: 1178-85

2016

Bragg F, Li L, Yang L, Guo Y, Chen Y, Bian Z, Chen J, **Collins R**, Peto R, Wang C, Dong C, Pan R, Zhou J, Xu X, Chen Z for the China Kadoorie Biobank Collaborative Group. Risks and population burden of cardiovascular diseases associated with diabetes in China: a prospective study of 0.5 million adults. *PLoS Med* 2016; 13: e1002026.6

Bragg F, Li L, Bennett D, Guo Y, Lewington S, Bian Z, Yang L, Chen J, Chen Y, **Collins R**, Peto R, Zhu B, Yin J, Hu X, Zhou L, Pan Y, Chen Z for the China Kadoorie Biobank (CKB) Collaborative Group. Association of random plasma glucose levels with the risk for cardiovascular disease among Chinese adults without known diabetes. *JAMA Cardiol* 2016; 1:813-823

Du H, Li L, Bennett D, Guo Y, Key TJ, Bian Z, Sherliker P, Gao H, Chen Y, Yang L, Chen J, Wang S, Du R, Su H, **Collins R**, Peto R, Chen Z. Fresh fruit consumption and major cardiovascular disease in China. *N Engl J Med* 2016; 374: 1332-43

Lewington S, Lacey B, Clarke R, Guo Y, Kong X, Yang L, Chen Y, Bian Z, Chen J, Meng J, Xiong Y, He T, Pang Z, Zhang S, **Collins R**, Peto R, Li L, Chen Z, for the China Kadoorie Biobank Consortium. The burden of hypertension and associated risk for cardiovascular mortality in China. *JAMA Int Med* 2016; 176: 524-32

Mihaylova B, Schlackow I, Herrington W, Lozano-Kühne J, Kent S, Emberson J, Reith C, Haynes R, Cass A, Craig J, Gray A, **Collins R**, Landray MJ, Baigent C, for the SHARP Collaborative Group. Cost-effectiveness of simvastatin plus ezetimibe for cardiovascular prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). *Am J Kid Dis* 2016; 67: 576-84

Millwood IY, Bennett DA, Walters RG, Clarke R, Waterworth D, Johnson T, Chen Y, Yang L, Guo Y, Bian Z, Hacker A, Yeo A, Parish S, Hill MR, Chisoe S, Peto R, Cardon L, **Collins R**, Li L, Chen Z. Lipoprotein-Associated Phospholipase A2 Loss-of-Function Variant and Risk of Vascular Diseases in 90,000 Chinese Adults. *J Am Coll Cardiol*. 2016; 6:230-231

Petersen S, Matthews P, Francis J, Robson M, Zemrak F, Boubertakh R, Young A, Hudson S, Weale P, Garratt S, **Collins R**, Piechnik S, Neubauer S. UK Biobank's cardiovascular magnetic resonance protocol. *JCMR* 2016; 18: 8

Millwood I, Bennett D, Walters R, Clarke R, Waterworth D, Johnson T, Chen Y, Yang L, Guo Y, Bian Z, Hacker A, Yeo A, Parish S, Hill M, Chisoe S, Peto R, Cardon L, **Collins R**, Li L and Chen Z, on behalf of the China Kadoorie Biobank Collaborative Group. A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults. *Int J Epidemiol* 2016; 45: 1588-1599

Alegre-Díaz J, Herrington W, López-Cervantes M, Gnatiuc L, Ramirez R, Hill M, Baigent C, McCarthy M, Lewington S, **Collins R**, Whitlock G, Tapia-Conyer R, Peto R, Kuri-Morales P, Emberson J. Diabetes and cause-specific mortality in Mexico City. *N Engl J Med* 2016; 375:1961-71

Loley C, Alver M, Assimes T L, Bjornes A, Goel A, Gustafsson S, Hernesniemi J, Hopewell J C, Kanoni S, Kleber M E, Lau K W, Lu Y, Lyytikäinen L-P, Nelson C P, Nikpay M, Qu L, Salfati E, Scholz M, Tukiainen T, Willenborg C, Won H-H, Zeng L, Zhang W, Anand S S, Beutner F, Bottinger E P, Clarke R, Dedoussis G, Do R, Esko T, Eskola M, Farrall M, Gauguier D, Giedraitis V, Granger C B, Hall A S, Hamsten A, Hazen S L, Huang J, Kähönen M, Kyriakou T, Laaksonen R, Lind L, Lindgren C, Magnusson P K E, Marouli E, Mihailov E, Morris A P, Nikus K, Pedersen N, Rallidis L, Salomaa V, Shah S H, Stewart A F R, Thompson J R, Zalloua P A, Chambers J C, **Collins R**, Ingelsson E, Iribarren C, Karhunen P J, Kooner J S, Lehtimäki T, Loos R J F, März W, McPherson R, Metspalu A, Reilly M P, Ripatti S, Sanghera D K, Thiery J, Watkins H, Deloukas P, Kathiresan S, Samani N J, Schunkert H,

Erdmann J, König I R. No association of coronary artery disease with X-chromosomal variants in comprehensive international meta-analysis. *Sci Rep.* 2016 12; 6: 35278

Miller K L, Alfaro-Almagro F, Bangerter N K, Thomas D L, Yacoub E, Xu J, Bartsch A J, Jbabdi S, Sotiropoulos S N, Andersson J L R, Griffanti L, Douaud G, Okell T W, Weale P, Dragonu J, Garratt S, Hudson S, **Collins R**, Jenkinson M, Matthews P M, Smith, S M. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. *Nat. Neuroscience* 2016; 19; 1523-1540

West J, Dahlqvist Leinhard O, Romu T, **Collins R**, Garratt S, Bell J, Borga M, Thomas L. Feasibility of MR-based body composition analysis in large scale population studies. *PLOS ONE* 2016; 11. DOI:10.1371/journal.pone.0163332

Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, **Collins R**, Casadei B. Perioperative rosuvastatin in cardiac surgery. *New Engl J Med* 2016; 374: 1744-53

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016; 388: 2532-2561

Armitage J, Baigent C, **Collins R**. Lessons from the controversy over statins - Authors' reply. *Lancet* 2016; 388: 2237-8.

Casadei B, **Collins R**, Zheng Z. Perioperative rosuvastatin in cardiac surgery (author's reply). *N Eng J Med* 2016; 375: 901-3

Herrington WG, Emberson J, Mihaylova B, **Collins R**, Baigent C, for the Cholesterol Treatment Trialists' Collaboration. Are statins useful in patients with advanced chronic kidney disease? - Authors' reply. *Lancet Diabetes Endocrinol* 2016; 4: 971-2

Reith C, Blackwell L, Emberson J, Mihaylova B, Armitage J, Fulcher J, Keech A, Simes J, Baigent C, **Collins R**, Reith C, Blackwell L. for the Cholesterol Treatment Trialists' Collaboration (CTT). Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. *American Heart Journal.* 2016; 176: 63-69.

Herrington W, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu M, Mark P, Fellström B, Jardine A, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray M, Keech A, Simes J, **Collins R**, and Baigent C. Cholesterol Treatment Trialists' (CTT) Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. *Lancet Diabetes Endocrinol.* 2016; 4: 829–839

Kent S, Haynes R, Hopewell, Parish, Gray A, Landray M, **Collins R**, Armitage J, Mihaylova B on behalf of the HPS2-THRIVE Collaborative Group. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. *Circ Cardiovasc Qual Outcomes* 2016; 9: 348-354

2017

Coffey S, Lewandowski AJ, Garratt S, Meijer R, Lynam S, Bedi R, Paterson J, Yaqub M, Noble J A, Neubauer S, Petersen S E, Allen N, Sudlow C, **Collins R**, Matthews M M and Leeson P. Protocol and quality assurance for carotid imaging in 100,000 participants of UK Biobank: development and assessment. *Eur J Prev Cardiol* 2017; 24: 1799-1806

Du H, Li L, Bennett D, Guo Y, Turnbull I, Yang L, Bragg F, Bian Z, Chen Y, Chen J, Millwood I, Sansome S, Ma L, Huang Y, Zhang N, Zheng X, Sun Q, Key T, **Collins R**, Peto R, Chen Z, China Kadoorie Biobank study. Fresh fruit consumption in relation to incident diabetes and diabetic vascular complications: A 7-y prospective study of 0.5 million Chinese adults. *PLoS Med* 2017; 14: e1002279

Bragg F, Holmes MV, Iona A, Guo Y, Du H, Chen Y, Bian Z, Yang L, Herrington W, Bennett D, Turnbull I, Liu Y, Feng S, Chen J, Clarke R, **Collins R**, Peto R, Li L, Chen Z, for the China Kadoorie Biobank

Collaborative Group. Association between diabetes and cause-specific mortality in rural and urban areas of China. *JAMA* 2017; 317: 280-289

Clarke R, Du H, Kurmi O, Parish S, Yang M, Arnold M, Guo Y, Bian Z, Wang L, Chen Y, Meijer R, Sansome S, McDonnell J, **Collins R**, Li L, Chen Z for the China Kadoorie Biobank Study Group. Burden of carotid artery atherosclerosis in Chinese adults: implications for future risk of cardiovascular diseases. *Eur J Prev Cardiol* 2017; 24: 647-656

Gnatiu L, Alegre-Díaz J, Halsey J, Herrington W G, López-Cervantes M, Lewington S, **Collins R**, Tapia-Conyer R, Peto R, Emberson J R, Kuri-Morales P. Adiposity and blood pressure in 110 000 Mexican adults. *Hypertension* 2017; 69: 608-14

REVEAL Collaborative Group Writing Committee: Bowman L, Chen F, Sammons E, Hopewell J C, Wallendszus K, Stevens W, Valdes-Marquez E, Wiviott S, Cannon C P, Braunwald E, **Collins R**, Landray M J. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) a large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: trial design, recruitment and baseline characteristics. *Am Heart J* 2017; 187: 182–190

Landray M J, Bax J J, Alliot L, Buyse M, Cohen A, **Collins R**, Hindricks G, James S K, Lane S, Maggioni A P, Meeker-O'Connell A, Olsson G, Pocock S J, Rawlins M, Sellors J, Shinagawa K, Sipido K R, Smeeth L, Stephens R, Stewart M W, Stough W G, Sweeney F, Van de Werf F, Woods K, Casadei B. Improving public health by improving clinical trial guidelines and their application. *Eur Heart J* 2017; 38: 1632-1637

Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, **Collins R**, Sever, P on behalf of the ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. *Lancet* 2017; 389: 2473-2481

Littlejohns T, Sudlow C, Allen N, **Collins R**. UK Biobank: opportunities for cardiovascular research. *Eur Heart J* 2017; 1-10.

Fry N, Littlejohns T, Sudlow C, Doherty N, Adamska L, Sprosen T, **Collins R**, Allen N. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with the general population *Am J Epidemiol* 2017; 186: 1026-1034.

Bennett D, Du H, Clarke R, Guo Y, Yang L, Bian Z, Chen Y, Millwood I, Yu C, He P, Zeng X, **Collins R**, Chen J, Peto R, Li L, Chen Z. Association of physical activity with risk of major cardiovascular diseases in Chinese men and women. *JAMA Cardiol* 2017; 2: 1349-1358.

Gibson L M, Littlejohns T J, Adamska L, Garratt S, Doherty N, Wardlaw J M, Maskell G, Parker M, Brownsword R, Matthews P M, **Collins R**, Allen N E, Sellors J, Sudlow C L M. Impact of detecting potentially serious incidental findings during multi-modal imaging. *Wellcome Open Res* 2017; 2: 114.

Millwood I, Li L, Smith M, Guo y, Ling Yang I, Bian Z, Lewington S, Whitlock G, Sherliker P, **Collins R**, Chen J, Peto R, Wang H, Xu J, He J, Yu M, Liu H, Chen Z on behalf of the China Kadoorie Biobank collaborative group. Alcohol consumption in 0.5 million people from 10 diverse regions of China: prevalence, patterns and socio-demographic and health-related correlates. *Int J Epidem* 2017; 46: 2103

Du H, Li L, Bennett D, Guo Y, Turnbull I, Yang L, Bragg F, Bian Z, Chen Y, Chen J, Millwood I, Sansome S, Ma L, Huang Y, Zhang N, Zheng X, Sun Q, Key T, **Collins R**, Peto R, Chen Z, China Kadoorie Biobank study. Fresh fruit consumption and all-cause and cause-specific mortality: findings from the China Kadoorie Biobank. *Int J Epidem* 2017; 46: 1444-55

Collins R, Armitage J, Baigent C, Smith GD, Smeeth L. Safety and efficacy of statins - Authors' reply. *Lancet* 2017; 389: 1099-100

HPS3/TIMI55–REVEAL Collaborative Group (**Collins R**; Chair, co-PI, and author). Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med* 2017; 377:1217-1227

2018

Boffa, M B, Koschinsky M L, Parish, S, Hopewell J.C, Hill M R, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen T R, Baigent C, **Collins R**, Landray M, Armitage J, on behalf of the HPS2-THRIVE Collaborative Group. Therapeutic lowering of Lipoprotein(a) a role for pharmacogenetics. *Circ Genom Precis Med* 2018; 11:e002052

Aung T, Halsey J, Kromhout D, Gerstein H, Marchioli R, Tavazzi L, Geleijnse J, Rauch B, Ness A, Galan P, Chew E, Bosch J, **Collins R**, Lewington S, Armitage J, Clarke R. Associations of Omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. *JAMA Cardiology* 2018; 3: 225-34

Bowman L, Mafham M, Stevens W, Haynes R, Aung T, Chen F, Buck G, **Collins R**, Armitage J; ASCEND Study Collaborative Group. ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. *Am Heart J* 2018; 198: 135-144

Bragg F, Tang K, Guo y, Iona A, Du H, Holmes M, Bian Z, Kartsonaki C, Chen Y, Yang L, Sun Q, Dong C, Chen J, **Collins R**, Peto R, Li L, Chen Z, for the China Kadoorie Biobank (CKB) Collaborative Group. Associations of general and central adiposity with incident diabetes in Chinese men and women. *Diabetes Care* 2018; 41: 494-502

Chen Z, Iona A, Parish S, Chen Y, Guo Y, Bragg F, Yang L, Bian Z, Holmes MV, Lewington S, Lacey B, Gao R, Liu F, Zhang Z, Chen J, Walters RG, **Collins R**, Clarke R, Peto R, Li L; China Kadoorie Biobank collaborative group. Adiposity and risk of ischaemic and haemorrhagic stroke in 0.5 million Chinese men and women: a prospective cohort study. *Lancet Glob Health* 2018; 6:e630-e640

ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, **Collins R**, Parish S, Armitage J. Effects of n-3 fatty acid supplements in diabetes mellitus. *N Engl J Med* 2018; 379:1540-1550.

ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, **Collins R**, Parish S, Armitage J. Effects of aspirin for primary prevention in persons with diabetes mellitus. *N Engl J Med* 2018; 379:1529-1539

Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, **Collins R**, Lewington S, Armitage J, Clarke R; Omega-3 Treatment Trialists' Collaboration. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. *JAMA Cardiol* 2018; 3: 225-234

Collins R. Back to the future: the urgent need to re-introduce streamlined trials. *European Heart Journal Supplements* 2018; 20(suppl C): C14-C7

Cholesterol Treatment Trialists' Collaboration, Including, Armitage J, Bowman L, **Collins R**, Baigent C, Davies C, Emberson J, Halls H, Harper C, Herrington W, Holland L, Landray M, Mihaylova M, Parish S, Peto R, Preiss D, Reith R, and Spata E, Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2018. 393: 407-415

Herrington WG, Alegre-Díaz J, Wade R, Gnatiuc L, Ramirez-Reyes R, Hill M, Solano-Sánchez M, Baigent C, Lewington S, Collins R, Tapia-Conyer R, Peto R, Kuri-Morales P, **Collins R**, Emberson JR. Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. *Lancet Diabetes Endocrinol* 2018; 6:455-463.

FitzGerald G, Botstein D, Califf R, **Collins R**. The future of humans as model organisms. *Science* 2018; 361: 552-3

Herrington WG, Alegre-Díaz J, Wade R, **Collins R**. Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. *Lancet Diabet & Endocrinol* 2018; 6: 455-63

Holmes MV, Millwood I, Kartsonaki C, et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. *J Am Coll Cardiol* 2018; 71: 620-32

Hopewell JC, Malik R, Valdés-Márquez E, Worrall BB, **Collins R**, METASTROKE Collaboration of the ISGC. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. *Eur Heart J* 2018; 39: 354-9

Kurmi O, Wang J, Bennett D, **Collins R**. Excess risk of major vascular diseases associated with air flow obstruction: a 9-year prospective study of 0.5 million Chinese adults. *Int J Chron Obst Pulm Dis* 2018; 13: 855-65

Lacey B, Lewington S, Clarke R, Kong X, Chen Y, Guo Y, Yang L, Bennett D, Bragg F, Bain Z, Wang S, Zhang H, Chen J, Walters R, **Collins R**, Peto R, Liming L, Chen Z and China Kadoorie Biobank Collaborative Group. Age-specific association between blood pressure and vascular and non-vascular chronic diseases in 0.5 million adults in China: a prospective cohort study. *Lancet Glob Health*. 2018; 6(6): e641–e649

Lewington S, Gnatiuc L, Herrington W, **Collins R**. Sex-specific relevance of diabetes to occlusive vascular and other mortality: Meta-analysis of individual data from 68 prospective studies with 77,000 deaths among 1 million adults. *Lancet Diabet & Endocrinol* 2018; 6: 538-46

Liu X, Bragg F, Yang L, Kartsonaki C, Guo Y, Du H, Bian Z, Chen Y, Yu C, Lv J, Wang K, Zhang H, Chen J, Clarke R, **Collins R**, Peto R, Li L, Chen Z for the China Kadoorie Biobank Collaborative Group. Smoking and smoking cessation in relation to risk of diabetes in Chinese men and women: a 9-year prospective study of 0.5 million people. *Lancet Public Health* 2018; 3: e167-e76

Walters R, Chen Z, for the China Kadoorie Biobank Collaborative Group. Association of CETP gene variants with risk for vascular and nonvascular diseases among chinese adults. *JAMA Cardiology* 2018; 3(1): 34-43

Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen T, Baigent C, **Collins R**, Landray M, Armitage J, on behalf of the HPS2-THRIVE Collaborative Group. Impact of Apolipoprotein(a) Isoform Size on Lp(a) Lowering in the HPS2-THRIVE Study. *Circ Cardiovasc Genet* 2018; 11: e001696-e

Peto R, **Collins R**. Trust the blinded randomized evidence that statin therapy rarely causes symptomatic side effects. *Circulation* 2018; 138:1499-1501

Offer A, Arnold M, Clarke R, Bennett D, Bowman L, Bulbulia R, Haynes R, Li J, Hopewell J C, Landray M, Armitage J, **Collins R**, Parish S; for the Heart Protection Study (HPS). Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), and Treatment of HDL (High-Density Lipoprotein) to Reduce the Incidence Vascular Events (HPS2-THRIVE) Collaborative Groups. Assessment of vascular event prevention and cognitive function among older adults with pre-existing vascular disease or diabetes: a secondary analysis of 3 randomized clinical trials. *JAMA Network Open* 2019; 2(3):e190223

Pang Y, Kartsonaki C, Du H, Millwood I, Chen Y, Yang L, Walters R, Bragg F, Peto R, Clarke R, **Collins R**, Bennett D, Holmes M, and Chen Z, Physical activity, sedentary leisure time, circulating metabolic markers and risk of major vascular diseases. *Circ Genom Precis Med* 2019; 12: 386-396

Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, **Collins R**, Landray M J, Gray A, Baigent C, Mihaylova B; on behalf of the SHARP Collaborative Group. Cost-effectiveness of lipid lowering statins and ezetimibe in chronic kidney disease. *Kidney Int* 2019; 96:170-179

Claussnitzer M, Cho J, **Collins R**, Cox N J, Dermitzakis E T, Hurles M E, Kathiresan S, Kenny E E, Lindgren CM, MaCarthur DG, North KN, Plon SE, Rehm HL, Risch N, Rotimi C, Shendure J, Soranzo N, McCarthy M. A brief history of human disease genetics. *Nature* 2020; 577: 179-189

Arnold M, Linden A, Clarke R, Guo Y, Du H, Bian Z, Wan E, Yang M, Wang Y, Wang L, Chen Y, Chen J, Long H, Gu Q, **Collins R**, Li L, Chen Z, Parish S and the China Kadoorie Biobank Collaborative Group. Carotid Intima-Media Thickness but not carotid artery plaque in healthy individuals is linked to lean body mass *J Am Heart Assoc.* 2019; 8:e01191

Adlam D, Olson TM, Combaret N, Kovacic JC, Iismaa SE, Al-Hussaini A, O'Byrne MM, Bouajila S, Georges A, Mishra K, Braund PS, d'Escamard V, Huang S, Margaritis M, Nelson CP, de Andrade M, Kadian-Dodov D, Welch CA, Mazurkiewicz S, Jeunemaitre X; DISCO Consortium, Wong CMY, Giannoulatou E, Sweeting M, Muller D, Wood A, McGrath-Cadell L, Fatkin D, Dunwoodie SL, Harvey R, Holloway C, Empana JP, Jouven X; CARDIoGRAMPlusC4D Study Group, Olin JW, Gulati R, Tweet MS, Hayes SN, Samani NJ, Graham RM, Motreff P, Bouatia-Naji N. Association of the PHACTR1/EDN1 genetic locus with spontaneous coronary artery dissection. *J Am Coll Cardiol* 2019; 8;73: 58-66

Conroy M, Sellors J, Effingham M, Littlejohns T, Boultonwood C, Gillions L, Sudlow C, **Collins R**, Allen N. The advantages of UK Biobank's open access strategy for health research. *J Intern Med* 2019; 286: 389-397

Parish S, Arnold M, Clarke R, Du H, Wan E, Kurmi O, Chen Y, Guo Y, Bian Z, **Collins R**, Li L, Chen Z; China Kadoorie Biobank Collaborative Group. Assessment of the role of carotid atherosclerosis in the association between major cardiovascular risk factors and ischemic stroke subtypes. *JAMA Netw Open* 2019; 3; 2(5): e194873

Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, Bennett DA, Chen Y, Dong C, Hu R, Zhou G, Yu B, Jia W, Parish S, Clarke R, Davey Smith G, **Collins R**, Holmes MV, Li L, Peto R, Chen Z; China Kadoorie Biobank Collaborative Group. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. *Lancet* 2019; 393: 1831-1842

Sun L, Clarke R, Bennett D, Guo Y, Walters RG, Hill M, Parish S, Millwood IY, Bian Z, Chen Y, Yu C, Lv J, **Collins R**, Chen J, Peto R, Li L, Chen Z; China Kadoorie Biobank Collaborative Group; International Steering Committee; International Co-ordinating Centre, Oxford; National Co-ordinating Centre, Beijing; Regional Co-ordinating Centres. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults. *Nat Med* 2019; 569-574

Gnatiuc L, Alegre-Díaz J, Wade R, Ramirez-Reyes R, Tapia-Conyer R, Garcilazo-Ávila A, Chiquete E, Gonzáles-Carballo C, Solano-Sanchez M, Clarke R, **Collins R**, Herrington WG, Hill M, Lewington S,

Peto R, Emberson JR, Kuri-Morales P. General and abdominal adiposity and mortality in Mexico City: A [rospective study of 150 000 Adults. *Ann Intern Med* 2019; 171: 397-405

Gray R, Bradley R, Braybrooke J, Clarke M, **Collins R**, Davies L, Dodwell D, Hills R, Z. Liu, McGale P, MacKinnon L, Pan H, Peto R, Taylor C, and for the Early Breast Cancer Trialists' Collaborative Group, Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *Lancet* 2019; 393: 1440-1452

Hopewell JC, Ibrahim M, Hill M, Shaw PM, Braunwald E, Blaustein RO, Bowman L, Landray MJ, Sabatine MS, **Collins R**; HPS3/TIMI55 - REVEAL Collaborative Group. Impact of ADCY9 Genotype on Response to Anacetrapib. *Circulation* 2019; 23;140: 891-8

Littlejohns TJ, Sudlow C, Allen NE, **Collins R**. UK Biobank: opportunities for cardiovascular research. *Eur Heart J* 2019; 40:1158-1166

Rutherford J. and **Collins R**, Reflections on Randomized Trials and Observational Studies "Big Is Beautiful" A Conversation With Sir Rory Collins, FRS. *Circulatio* 2019; 140: 4-10

2020

Chen Z, Emberson J, **Collins R**, Strategic need for large prospective studies in different populations. *JAMA*; 2020; 323: 309-310

Mafham M, Spata E, Goldacre R, Gair D, Curnow P, Bray M, Hollings S, Roebuck C, Gale C, Mamas M, Deanfield J, de Belder M, Luescher T, Denwood T, Landray M, Emberson J, **Collins R**, Morris E, Casadei B, Baigent B. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. *Lancet*. 2020; 396: 381-389

Parish S, Mafham M, Offer A, Barton J, Wallendszus K, Stevens W, Buck G, Haynes R, **Collins R**, Bowman L, Armitage J; on behalf of the ASCEND Study Collaborative Group. Effects of Omega-3 Fatty Acid Supplements on Arrhythmias. *Circulation*, 2020; 141:331-333

Collins R, Bowman L, Landray M, Peto R. The Magic of Randomization versus the Myth of Real-World Evidence. *New Eng J Med*. 2020; 382: 674-678

Collins R, Bowman L, and Landray M, Randomization versus Real-World Evidence. Reply. *New Eng J Med* 2020; 383: p. e21

Hopewell JC, Offer A, Haynes R, Bowman L, Li J, Chen F, Bulbulia R, Lathrop M, Baigent C, Landray MJ, **Collins R**, Armitage J, Parish S. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. *Eur Heart J* 2020; 41: 3336-3342

Allen N, Arnold M, Parish S, Hill M, Sheard S, Callen H, Fry D, Moffat S, Gordon M, Welsh S, Elliott P, **Collins R**. Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK Biobank. *Wellcome Open Res* 2021; 5: 222

Wade R, Herrington W, Lewington S, Peto R, Gnatiuc L, Emberson J, Tapia-Conyer R, Ramirez-Reyes R, Kuri-Morales P, Alegre-Díaz J, Clarke R, & **Collins R**. Association of blood pressure with cause-specific mortality in Mexican adults. *JAMA Network Open* 2020; 3(9)

Littlejohns TJ, Holliday J, Gibson LM, Garratt S, Oesingmann N, Alfaro-Almagro F, Bell JD, Boulwood C, **Collins R**, Conroy MC, Crabtree N, Doherty N, Frangi AF, Harvey NC, Leeson P, Miller KL, Neubauer S, Petersen SE, Sellors J, Sheard S, Smith SM, Sudlow CLM, Matthews PM, Allen NE. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. *Nat Commun* 2020; 26; 11: 2624

Fulcher J, Keech A, Simes J, Baigent C, **Collins R**. Questioning statin therapy for older patients - Authors' reply. *Lancet* 2020; 13: 395:1 832-1833

Chen Y, Wright N, Guo Y, Turnbull I, Kartsonaki C, Yang L, Bian Z, Pei P, Pan D, Zhang Y, Qin H, Wang Y, Lv J, Liu M, Hao Z, Wang Y, Yu C, Peto R, **Collins R**, Li L, Clarke R, Chen Z; China Kadoorie Biobank Collaborative Group. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0.5 million Chinese adults. *Lancet Glob Health* 2020; (4): e580-e590

Chen Z, Emberson J, **Collins R**. Strategic Need for Large Prospective Studies in Different Populations. *JAMA* 2020; 28: 323: 309-310

2021

Aguilar-Ramirez D, Gnatiuc L, Wade R, Hill M, **Collins R**, Peto R, Emberson J, Herrington W. Changes in the diagnosis and management of diabetes in Mexico City between 1998-2004 and 2015-19. *Diabetes Care* 2021; 44: 944-951

Morris E, Goldacre R, Spata E, Mafham M, Finan P, Shelton J, Richards M, Spencer K, Emberson J, Hollings S, Curnow P, Gair D, Sebag-Montefiore D, Cunningham C, Rutter M, Nicholson B, Rashbass J, Landray M, **Collins R**, Casadei B, Baigent C. Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study. *Lancet Gastroenterology and Hepatology* 2021; 6:199-208

Aguilar-Ramirez D, Alegre-Díaz J, Herrington WG, Staplin N, Ramirez-Reyes R, Gnatiuc L, Hill M, Romer F, Torres J, Trichia E, Wade R, **Collins R**, Emberson RE, Kuri-Morales P, Tapia-Conyer R. Association of kidney function with NMR-Quantified lipids, lipoproteins, and metabolic measures in Mexican adults. *J Clin Epi & Metab* 2021; 106: 2828-2839

Dubinsky MC, **Collins R**, Abreu MT. Challenges and opportunities in IBD clinical trial design. *Gastroenterology*. 2021; 161: 400-404

Thomson B, Tapia-Conyer R, Lacey B, Lewington S, Ramirez-Reyes R, Aguilar-Ramirez D, Gnatiuc L, Herrington WG, Torres J, Trichia E, Wade R, **Collins R**, Peto R, Kuri-Morales P, Alegre-Díaz J, Emberson JR. Low-intensity daily smoking and cause-specific mortality in Mexico: prospective study of 150 000 adults. *Int J Epi* 2021; 50 955-964.

Caleyachetty R, Littlejohns T, Lacey B, Bešević J, Conroy M, **Collins R**, Allen N, United Kingdom Biobank (UK Biobank): JACC Focus Seminar 6/8. *JACC* 2021; 78: 56-65

Akbari P, Gilani A, Sosina O, Kosmicki JA, Khrimian L, Fang YY, Persaud T, Garcia V, Sun D, Li A, Mbatchou J, Locke AE, Benner C, Verweij N, Lin N, Hossain S, Agostinucci K, Pascale JV, Dirice E, Dunn M; Regeneron Genetics Center; DiscovEHR Collaboration, Kraus WE, Shah SH, Chen YI, Rotter JI, Rader DJ, Melander O, Still CD, Mirshahi T, Carey DJ, Berumen-Campos J, Kuri-Morales P, Alegre-Díaz J, Torres JM, Emberson JR, **Collins R**, Balasubramanian S, Hawes A, Jones M, Zambrowicz B, Murphy AJ, Paulding C, Coppola G, Overton JD, Reid JG, Shuldiner AR, Cantor M, Kang HM, Abecasis GR, Karalis K, Economides AN, Marchini J, Yancopoulos GD, Sleeman MW, Altarejos J, Della Gatta G, Tapia-Conyer R, Schwartzman ML, Baras A, Ferreira MAR, Lotta LA. Sequencing of 640,000 exomes identifies *GPR75* variants associated with protection from obesity. *Science* 2021; 373: 8683.

Allen NE, Arnold M, Parish S, Hill M, Sheard S, Callen H, Fry D, Moffat S, Gordon M, Welsh S, Elliott P, **Collins R**. Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK Biobank. *Wellcome Open Res* 2021; 4; 5: 222

Gnatiuc L, Tapia-Conyer R, Wade R, Ramirez-Reyes R, Aguilar-Ramirez D, Herrington W, Hill M, Lewington S, Torres J, Trichia E, **Collins R**, Peto R, Clarke R, Kuri-Morales P, Emberson JR, Alegre-Díaz J. Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults. *Eur J Prev Cardiol* 2021: 9;zwab038

2022

van der Veere P, Hammami I, Buck G, Greenland M, Offer A, Nunn M, Whiteley W, Bulbulia R, **Collins R**, Armitage J, Mafham M, Parish S, Heart Protection Study Collaborative Group. Weight loss in a cardiovascular trial population identifies people at future risk of dementia. *Alzheimer's Dement* 2022; 14:e12352

Wang W, Lv J, Yu C, Guo Y, Pei P, Zhuang Z, Yang L, Millwood IY, Walters RG, Chen Y, Du H, Wu X, Chen J, Chen Z, Clarke R, **Collins R**, Huang T, Li L, China Kadoorie Biobank Collaborative Group. Lifestyle factors and fetal and childhood origins of type 2 diabetes: a prospective study of Chinese and European adults. *Am J Clin Nut* 2022; 115: 749-758

Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, Lange F, Andersson JLR, Griffanti L, Duff E, Jbabdi S, Taschler B, Keating P, Winkler AM, **Collins R**, Matthews PM, Allen N, Miller KL, Nichols TE, Smith SM. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *Nature* 2022; 604: 697-707

Mentzer AJ, Brenner N, Allen N, Littlejohns TJ, Chong AY, Cortes A, Almond R, Hill M, Sheard S, McVean G, **Collins R**, Hill AVS, Waterboer T. UKB Infection Advisory Board. Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. *Nat Commun* 2022; 13; <https://doi.org/10.1038/s41467-022-29307-3>

HPS3/TIMI55-REVEAL Collaborative Group None., Writing Committee, Sammons E, Hopewell JC, Chen F, Stevens W, Wallendszus K, Valdes-Marquez E, Dayanandan R, Knott C, Murphy K, Wincott E, Baxter A, Goodenough R, Lay M, Hill M, Macdonnell S, Fabbri G, Lucci D, Fajardo-Moser M, Brenner S, Hao D, Zhang H, Liu J, Wuhan B., Mosegaard S, Herrington W, Wannner C, Angermann C, Ertl G, Maggioni A, Barter P, Mihaylova B, Mitchel Y, Blaustein R, Goto S, Tobert J, DeLucca P, Chen Y, Chen Z., Gray A., Haynes R., Armitage J, Baigent C, Wiviott S, Cannon C, Braunwald E., **Collins R**, Bowman L, Landray M, REVEAL Collaborative Group. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. *Eur Heart J* 2022; 43: 1416-1424

Gnatiuc L, Tapia-Conyer R, Wade R, Ramirez-Reyes R, Aguilar-Ramirez D, Herrington W, Hill M, Lewington S, Torres J, Trichia E, **Collins R**, Peto R, Clarke R, Kuri-Morales P, Emberson JR, Alegre-Díaz J. Abdominal and gluteo-femoral markers of adiposity and risk of vascular-metabolic mortality in a prospective study of 150 000 Mexican adults. *Eur J Prev Cardiol* 2022; 29: 730-738

Kakkoura MG, Du H, Guo Y, Yu C, Yang L, Pei P, Chen Y, Sansome S, Chan WC, Yang X, Fan L, Lv J, Chen J, Li L, Key TJ, Chen Z, **Collins R**. China Kadoorie Biobank (CKB) Collaborative Group. Dairy consumption and risks of total and site-specific cancers in Chinese adults: an 11-year prospective study of 0.5 million people. *BMC Med* 2022; 20:134

Yang R, Lv J, Yu C, Guo Y, Bian Z, Han Y, Yang L, Chen Y, Du H, Liu J, Qu C, Chen J, Chen Z, Clarke R, Huang T, **Collins R**, Li L, China Kadoorie Biobank Collaborative Group. Importance of healthy lifestyle factors and ideal cardiovascular health metrics for risk of heart failure in Chinese adults. *Int J Epidemiol* 2022; 51: 567-578

Parish S, Mafham M, Offer A, Barton J, Wallendszus K, Stevens W, Buck G, Haynes R, **Collins R**, Bowman L, Armitage J. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. *Eur Heart J* 2022; 43: 2010-2019

Yang J, Du H, Guo Y, Bian Z, Yu C, Chen Y, Yang L, Liu J, Han X, Chen J, Lv J, Li L, Chen Z, **Collins R**. Coarse grain consumption and risk of cardiometabolic diseases: a prospective cohort study of Chinese adults. China Kadoorie Biobank Collaborative Group. *J Nutr.* 2022; 152: 1476-1486

Alegre-Díaz J, Friedrichs LG, Ramirez-Reyes R, Wade R, Bragg F, Herrington WG, Clarke R, Peto R, **Collins R**, Kuri-Morales P, Emberson J, Tapia-Conyer R. Body mass index and COVID-19 mortality: prospective study of 120000 Mexican adults. *Int J Epidemiol* 2022; 51: 1698-1700

Cholesterol Treatment Trialists' (CTT) Collaborators (writing committee: Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Simes J, **Collins R**). Treatment C. Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. *Clinical Trials* 2022; 19: 593-604

Cholesterol Treatment Trialists' (CTT) Collaborators (writing committee:Baigent C, Reith C, Emberson J, **Collins R**, Preiss D, Spata E, Halls H, Holland L, Armitage A, Blackwell L. Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy. *Lancet* 2022; 400: 832-45

Bešević J, Lacey B, Conroy M, Omiyale W, Feng Q, **Collins R**, Allen N. New Horizons: the value of UK Biobank to research on endocrine and metabolic disorders. *J Clin Endocrinol Metab* 2022; 107: 2403-2410

Akbari P, Sosina O, Bovijn J, Landheer K, Nielsen J, Kim M, Aykul S, De T, Haas ME, Hindy G, Lin N., Dinsmore I, Luo J, Hectors S, Geraghty B, Germino M, Panagis L, Parasoglou P, Walls JR, Halasz G., Atwal GS., Regeneron Genetics Center None, DiscovEHR Collaboration None, Jones M, LeBlanc M, Still C, Carey D, Giontella A, Orho-Melander M, Berumen J, Kuri-Morales P, Alegre-Díaz J, Torres J, Emberson J, **Collins R**, Rader DJ., Zambrowicz B, Murphy AJ, Balasubramanian S, Overton JD, Reid JG, Shuldiner AR, Cantor M, Abecasis GR, Ferreira MAR, Sleeman MW, Gusarova V, Altarejos J, Harris C., Economides A., Idone V, Karalis K., Della Gatta G, Mirshahi T, Yancopoulos G, Melander O, Marchini J, Tapia-Conyer R, Locke A, Baras A, Verweij N, Lotta L. Multiancestry exome sequencing reveals *INHBE* mutations associated with favorable fat distribution and protection from diabetes. *Nat Commun* 2022; 13: 4844

Aguilar-Ramirez D, Herrington WG, Alegre-Díaz J, Staplin N., Ramírez-Reyes R., Gnatiuc LF., Hill M, Romer F, Trichia E, Bragg F, Wade R, Lewington S, **Collins R**, Emberson J, Kuri-Morales P, Tapia-Conyer R. Adiposity and NMR-measured lipid and metabolic biomarkers among 30,000 Mexican adults. *Commun Med* 2022; 2:143

Nag A, Dhindsa R, Mitchell J, Vasavda C, Harper AR, Vitsios D, Ahnmark A, Bilican B, Madeyski-Bengtson K, Zarrouki B, Zoghbi AW, Wang Q, Smith K, Alegre-Díaz J, Kuri-Morales P, Berumen J, Tapia-Conyer R, Emberson J, Torres J, **Collins R**, Smith DM, Challis B, Paul D, Bohlooly-Y M, Snowden M, Baker D, Fritsche-Danielson R, Pangalos M, Petrovski S. Human genetics uncovers MAP3K15 as an obesity-independent therapeutic target for diabetes. *Sci Adv* 2022; 8: 46

Conroy M, Lacey B, Bešević J, Omiyale W, Feng Q, Effingham M, Sellers J, Sheard S, Pancholi M, Gregory G, Busby J, **Collins R**, Allen NE. UK Biobank: a globally important resource for cancer research. *Br J Cancer* 2022 <https://doi.org/10.1038/s41416-022-02053-5>

Chan K, Wright N, Xiao D, Guo Y, Chen Y, Du H, Yang L, Millwood I, Pei P, Wang J, Turnbull I, Gilbert S, Avery D, Kartsonaki C, Yu C, Chen J, Lv J, Clarke R, **Collins R**, Peto R, Li L, Wang C, Chen Z. China Kadoorie Biobank collaborative group. Tobacco smoking and risks of more than 470 diseases in China: a prospective cohort study. *Lancet* 2022; 7: e1014-e1026

Wijesurendra R, Sardell R, Hill M, Jayaram R, **Collins R**, Chen Z, Haynes R, Staplin N, Casadei B. 83 Determinants of post-operative atrial fibrillation in 1613 patients undergoing coronary artery bypass grafting in the statin therapy in cardiac surgery (STICS) trial. *Heart* 2022; 108: A61-A62